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 In the course of metazoan embryonic and post-embryonic development, 
more cells are generated than exist in the mature organism, and these cells are 
deleted by the process of programmed cell death.  In addition, cells can be 
pushed toward death when they accumulate genetic errors, are virally-infected or 
are otherwise deemed potentially-harmful to the overall organism.  
Caenorhabditis elegans has proved to be an excellent model system for 
elucidating the genetic underpinnings of cell death, and research has shown that 
the core machinery, made up of the egl-1, ced-9, ced-4 and ced-3 genes, is 
conserved across metazoans, and their homologues are crucial for such 
diseases as cancer, neurodegeneration and autoimmunity.  We used the C. 
elegans tail-spike cell as a model to uncover dre-1/FBXO11 as a conserved 
apoptotic regulator that controls tail-spike cell death and also plays a role in 
human lymphoma. 
 The tail-spike cell is unique among cells fated for programmed cell death 
in two ways.  First, unlike most dying C. elegans cells, the tail-spike cell lives for 
several hours before its demise, and during this time differentiates.  In 
comparison, most cells die minutes after birth as undifferentiated cells.  Second, 
while tail-spike cell death requires both the CED-3 caspase and CED-4/Apaf-1 
adaptor proteins, the BH3-only protein EGL-1 is dispensable.  Thus, other 
gene(s) substitute for egl-1's role as a regulator of caspase activation in this cell, 
and we set out to identify the relevant gene or genes. 
 A screen for mutants in which the tail-spike cell survives inappropriately 
yielded a mutant, ns39, in which the ced-3 caspase is transcribed as normal, but 
fails to become activated.  We mapped and cloned this mutant, and found that 
dre-1 (daf-12-redundant-1) is required for caspase activation in the tail-spike cell.  
Expression of the dre-1 cDNA in the tail-spike cell rescues the dre-1(ns39) defect 
in a cell autonomous manner, and expression studies show that dre-1 is 
expressed in the tail-spike cell.  Partial loss-of-function alleles of dre-1, when 
combined with weak loss-of-function alleles of ced-3 and ced-4, a null allele of 
egl-1, or a weak gain-of-function allele of ced-9 exhibit a synergistic loss of tail-
spike cell death.  A null allele of ced-9, however, when combined with a strong 
loss-of-function dre-1 allele, suppresses the tail-spike cell death phenotype of the 
dre-1(ns39).  This epistatic relationship shows that dre-1 acts upstream of, or in 
parallel to ced-9.  These results show that dre-1 has a central role in tail-spike 
cell death, and are consistent with it acting in place of egl-1 to promote tail-spike 
cell death. 
 DRE-1 is an F box protein, and we showed via RNAi and genetic 
experiments that DRE-1 acts in an SCF complex with CUL-1 and SKR-1 to 
regulate tail-spike cell death, and present evidence that DRE-1 and CED-9 bind 
to each other in vitro.  These results suggest a model in which the dre-1 SCF 
complex ubiquitinates CED-9 to eliminate its anti-apoptotic function and open the 
way for the cell to die. 
 A collaboration with Louis Staudt and Lixin Rui at the National Cancer 
Institute revealed that dre-1ʼs human homologue, FBXO11 is mutated or deleted 
in 5% of germinal center-like diffuse large B cell lymphomas, and that 
reintroduction of the gene into lymphoma cell lines that have deleted it induces 
apoptosis.  In addition, FBXO11 binds to BCL2 in lymphoma cell lines and 
induces the degradation of BCL2, and expression of BCL2 rescues the toxicity of 
FBXO11. 
 Taken together, our results establish dre-1/FBXO11 as a regulator of 
apoptosis in C. elegans and human lymphoma, and suggest a model in which 
DRE-1/FBXO11 ubiquitinates and degrades BCL2, a major anti-apoptotic protein. 
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Chapter 1:  Introduction 
 
In the development of nearly all metazoans, more cells are generated than 
exist in the mature animal, and these cells extra cells are fated to die by the 
process known as programmed cell death or apoptosis. While developmental cell 
deaths were first observed in the 19th century, the appreciation that these were a 
normal facet of producing a multicellular organism did not arrive until 
Glucksmanns work in the 1950s (Glucksmann, 1951).  His descriptive review set 
the stage for future studies on apoptosis. 
 
Genetic control of programmed cell death 
A major advance in understanding the genetic basis of this process came 
in H. Robert Horvitzs lab in the 1980s and 90s, when the first genetic mutants 
were isolated in which cell deaths failed to occur.  Sulston and Horvitz (Sulston 
and Horvitz, 1977) had recognized that Nomarski differential interference contrast 
microscopy could be used to identify dying cells as they become round corpses.  
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A screen in a ced-1 engulfment-defective background, in which corpses persist 
and are easily identified, yielded the ced-3(n717) mutant, in which nearly all cell 
deaths are eliminated, yet no changes occur in the stereotyped cell lineage (Ellis 
and Horvitz, 1986).  egl-1 had been previously isolated and recognized to involve 
deaths of the hermaphrodite-specific neurons (HSNs) that control egg-laying, and 
ced-4(n1162) was isolated as a suppressor of egl-1(n1084) (Ellis and Horvitz, 
1986).  Finally, ced-9 was isolated as a gain-of-function allele in a similar screen 
for inappropriate survival, and was shown to act as an anti-apoptotic gene 
(Hengartner et al., 1992).  These results defined C. elegans as an ideal system 
for identifying cell death regulators, established the counting of extra cells in the 
anterior pharynx as a technique for assessing cell death, and ordered these 
genes into a genetic pathway (Fig. 1). 
 
egl-1      ced-9  ced-4       ced-3  Apoptosis 
(BH3-only)    (BCL2)          (Apaf1)    (caspase) 
 
 
Fig. 1.  The core cell death machinery in C. elegans and their vertebrate 
homologues. 
 
 
When the molecular identities of the core apoptotic machinery were 
elucidated, the field had its first inklings of what the mechanism of cell death 
might be, and that these genes were conserved in sequence and function across 
metazoans (Conradt and Horvitz, 1998; Hengartner et al., 1992; Yuan and 
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Horvitz, 1992; Yuan et al., 1993).  ced-3 was found to encode a cysteine 
protease, similar to the vertebrate interleukin-1-converting enzyme (Yuan et al., 
1993).  A novel class of proteins was identified with the cloning of ced-4 (Yuan 
and Horvitz, 1992), but later was found to be homologous to the mammalian 
Apaf-1 gene (Zou et al., 1997).   BCL2 had been previously cloned as the gene 
translocated to the immunoglobulin locus in human follicular lymphoma, and 
shown to prevent cell death in B cells and T cells (Tsujimoto et al., 1984; Vaux et 
al., 1988).  Thus, the connection to BCL2 was immediately made when ced-9, its 
homologue, was identified (Hengartner et al., 1992) and further when the 
molecular nature of ced-9(n1950) was elucidated (Hengartner and Horvitz, 1994).  
Finally, when egl-1 was identified and shown to be a pro-apoptotic gene 
containing a BCL2-homology-3 (BH3) domain, it fit well with the cloning in the 
preceding years of several mammalian cell death activators with BH3 domains: 
Bid, Bad, Bax and Bak.  Thus, the C. elegans core apoptotic machinery was 
identified and models for its function were proposed and later validated. 
The current model for activation of programmed cell death in C. elegans 
(Fig. 2) begins with a cell not yet fated to die, in which CED-9 protein is tethered 
to the mitochondrial outer membrane, and a CED-4 dimer is being held inactive 
by CED-9.  This complex prevents CED-4 from binding to inactive CED-3, which 
is cytosolic and most-likely inherited (Maurer et al., 2007).  Thus the cell has the 
potential to undergo apoptosis, but remains alive until an initiating stimulus 
induces its death (Shaham and Horvitz, 1996a).  When EGL-1 is expressed, it 
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binds to CED-9, inducing a conformational change that results in the release of 
CED-4.  Now free from CED-9 inhibition, CED-4 forms a higher order structure, 
the “apoptosome” which binds to cytosolic CED-3, bringing the protease into 
position to be cleaved and become active.  Active CED-3 further cleaves CED-3 
zymogens and soon, through a feed forward mechanism, all CED-3 becomes 
active.  The active protease cleaves cellular proteins after aspartate residues, 
rapidly dismantling the cell. 
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Fig. 2.  The current model for the apoptotic pathway in C. elegans. 
In most or all cells, inactive CED-3 zymogen is available in the cytosol, while 
CED-9 is tethered to the mitochondrial membrane and holds CED-4 inactive.  
Once the apoptotic pathway is engaged, egl-1 is transcribed.  The EGL-1 protein 
binds to CED-9, releasing CED-4, which forms an oligomer.  This complex 
associates with CED-3, leading to its proteolytic cleavage and activation.  Active 
CED-3 dismantles the cell. 
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The tail-spike cell as a model for investigating programmed cell death 
John Sulston, in his landmark paper, The Embryonic Cell Lineage of the 
Nematode Caenorhabditis elegans, described his observations regarding cell 
death: 
“In the course of the lineage, one in six of all cells produced subsequently 
dies; their identity and the approximate times of their deaths are predictable.  The 
mode of death is similar to that seen previously in the postembryonic lineages.  In 
some cases death occurs several hours after birth, so that it is possible for the 
cells to function in some manner before being discarded.  A good example is the 
pair of tail spike cells, which fuse together, form a slender bundle of filaments in 
the tip of the tail, and then die.  At the other extreme are the majority of 
programmed deaths, which occur 20 to 30 min after birth; these cells are born 
with very little cytoplasm, and die without differentiating in any obvious way 
(Sulston et al., 1983).” 
Sulstons short paragraph forms the foundation for this thesis project.  
Because screens for global cell death regulators have already been carried out, 
we chose to study the death of an individual cell, with the hope of uncovering 
novel regulators of apoptosis.  But which one to choose?  The tail-spike cell was 
an inviting model for the reasons suggested by Sulston.  First, the cell appears to 
have a function before its death – to pattern its sister cell, hyp10, by extending a 
process into the tail spike around which hyp10 is wrapped.  Second, the tail-spike 
cell is unique in its morphology as well as in the timing of its death.  Most cell 
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deaths occur in small, undifferentiated cells with very little cytoplasm, and death 
occurs almost immediately after the birth of the cell.  These small cells are most 
likely produced by asymmetric cell division and have no function in the animal.  
The tail-spike cell, on the other hand, lives about 10 times as long and is thus 
similar to cells that die in mammals and other organisms, where the majority of 
deaths occur in differentiated cells that receive a signal to die.  Thus, what we 
learn about tail-spike cell death may be more relevant to cell death biology 
outside C. elegans; many developmental deaths in vertebrates occur in cells that 
have lived for a long period of time and differentiated fully (Meier et al., 2000). 
Following Sulstons description above, electron micrographs confirmed the 
anatomy of hyp10 and the tail-spike cell, but the tail-spike cell was not studied 
until recently, when Carine Maurer undertook its study as a model for 
understanding cell death.  The first step in understanding tail-spike cell death was 
to develop a specific fluorescent marker for the cell so that its status as alive or 
dead could be readily assessed.  While a 1.5 kb promoter fragment from the ced-
3 gene drove GFP expression in the cell, it also led to inappropriate survival in 
many animals, presumably by preventing endogenous ced-3 transcription in the 
cell.  Using a 690 bp fragment of the C. briggsae ced-3 gene retained the GFP 
expression but also eliminated the cell death defect.  This transgene was 
integrated and carries the name nsIs25.  It was used in all remaining tail-spike 
cell studies. 
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With a simple assay for tail-spike cell death, i.e., presence or absence of 
the GFP-labeled cell, genetic mutants could be used to determine which genes 
are required for tail-spike cell death.  Like most cell deaths in the worm, ced-3 
and ced-4 were required for this cell to die; 100% of animals harboring null 
mutations in ced-3 or ced-4 had inappropriately surviving tail-spike cells.  While 
this result was unsurprising, that egl-1 is not required was unexpected.  In egl-1 
null animals, 30% of animals had a surviving tail-spike cell, compared to a 
complete block in pharyngeal cell death.  This result points out that the tail-spike 
cell is an interesting model for another reason beyond Sulstons initial 
observations: even in the absence of egl-1 activity, the tail-spike cell is able to 
“know” that it is fated for death and to execute that death normally in 70% of 
animals.  egl-1 is not required for germline cell death (Gumienny et al., 1999), but 
does control the vast majority of somatic deaths by inhibiting ced-9.  In the tail-
spike cell, however, other gene(s) must serve egl-1s function as an upstream 
control of apoptosis.  Maurer et al. also showed that the residual egl-1 activity, 
though comparatively minor, fully requires ced-9 for its function; ced-9;egl-1 
double mutants had 0% tail-spike cell survival, showing that egl-1 acts through 
ced-9 in the tail-spike cell.  In addition, the ced-9 gain-of-function allele n1950 
has a weak effect on tail-spike cell death (3% survival), suggesting that, again, 
the tail-spike cell is unique in its cell death mechanisms (Maurer et al., 2007). 
Analysis of the ced-3 promoter identified three regions conserved between 
C. elegans and C. briggsae that are required for ced-3pro::gfp expression in the 
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tail-spike cell and induction of cell death.  A screen for lack of ced-3pro::gfp 
expression in the tail-spike cell identified several mutants, including two, ns114 
and ns115, that mapped to the homeodomain transcription factor pal-1.  In these 
mutants, ced-3 transcription was reduced, leading to weaker or no GFP 
expression as well as inappropriate survival of the tail-spike cell.  Electrophoretic 
mobility shift assays showed that pal-1 binds to the ced-3 promoter in two of the 
regions required for tail-spike cell ced-3pro::gfp expression, suggesting that pal-1 
regulates tail-spike cell death by inducing ced-3 transcription during late 
embryogenesis, and providing the downstream cue for the cell to die (Maurer et 
al., 2007).  Intriguingly, pal-1 is homologous to mouse Cdx2 which has been 
shown to be a tumor suppressor in mouse gut (Aoki et al., 2003; Bonhomme et 
al., 2003). 
 
 
The ubiquitin proteasome system and its role in cell death regulation 
 All biologic processes at their core are chemical reactions, and, as any 
high school chemistry student knows, the concentrations of reactants and 
products are crucial to determining which reactions will occur and how quickly.  
Thus, it is not surprising that much of biological regulation occurs via 
perturbations of protein levels.  For the purposes of increasing protein amounts, a 
vast array of mechanisms have evolved: transcription factors, chromatin 
modifications, mRNA trafficking, nuclear receptors and more.  Fewer modes exist 
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for eliminating proteins, and one system is dominant, perhaps because of the 
specificity it imparts: the ubiquitin-proteasome system. 
Ubiquitin-mediated protein degradation consists of two steps: first, a target 
protein is covalently modified with a chain of ubiquitin molecules; second, the 
26S proteasome uses ATP to proteolyze it.  In addition to the proteasome and 
ubiquitin, E1, E2 and E3 enzymes are required, and these may be single 
molecules or multi-subunit complexes.  Initially, a ubiquitin monomer is covalently 
conjugated to a cysteine residue on one of the few E1s (only one exists in C. 
elegans, uba-1).  This reaction requires ATP.  The ubiquitin is then transferred to 
an E2, of which there are more in most genomes; in the human there are about 
20 and in the C. elegans genome there are 22 ubc genes.  Finally, the ubiquitin is 
conjugated to its target protein in a reaction that is catalyzed by the E3, the 
substrate-specificity protein.  Because of this specificity requirement, a huge 
number of E3s have been identified in genomes, including hundreds in humans 
(Hicke et al., 2005; Hoeller et al., 2006).  Ubiquitins C-terminal glycine is 
attached with an isopeptide bond to a lysine on the target molecule, followed by 
repeated conjugations until a polyubiquitin chain is produced; at least four 
ubiquitin monomers are required for trafficking to the proteasome. 
 The proteasome is a large, multi-subunit complex made up of a 20S core 
and two 19S regulatory subunits.  The 20S core contains four stacked rings 
made up of seven  subunits in the two outer rings and seven  subunits in the 
inner rings (Besche et al., 2009).  On the inside surface of the cylinder are six 
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proteolytic sites that have chymotrypsin-like, trypsin-like and peptidylglutamyl 
peptide hydrolytic activities; these active sites digest the substrates into 7-9 
residue peptides (Voges et al., 1999). 
Because the proteasome is an efficient means to destroy cellular contents, 
its gating must be tightly controlled.  The gating mechanism involves the N-
terminal tails of the  subunits which extend into the central pore and block its 
opening until the 19S regulatory particle induces their opening (Groll et al., 2000).  
This ungating requires ATP hydrolysis through the six ATPase subunits of the 
19S particle.  In addition, ATP is required for unfolding of the target protein and 
for its entry into the core (Smith et al., 2005).  The 19S regulatory subunit binds 
to the polyubiquitin chain, and this transduces opening of the 20S gate (Bech-
Otschir et al., 2009; Li and Demartino, 2009).  The binding of polyubiquitin to the 
Usp14/Ubp6 subunit of the 19S particle appears crucial, as this triggers gate 
opening, leading to translocation of the target protein into the core and 
subsequent proteolysis (Peth et al., 2009).  Further work, especially a high 
resolution structure of the 19S particle, is necessary for complete understanding 
of this complex machine. 
 Proteolysis can only be an effective form of regulation if there is specificity 
about which proteins are degraded at which times.  The specificity in the 
ubiquitin-proteasome system comes from E3 ligases, of which there are two 
major types in eukaryotes: HECT domain-containing and RING domain-
containing.  HECT (homologous to E6-AP C-terminus) domain E3s possess 
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catalytic activity in that the ubiquitin moiety is covalently attached to the E3 from 
the E2, and this monomer is then passed to the substrate.  The HECT domain is 
the site of interaction with the E2 and consists of ~350 amino acids, including the 
cysteine which receives the ubiquitin monomer (Scheffner and Staub, 2007).  28 
HECT domain-containing genes occur in the human genome, including E6-AP 
(human papilloma virus E6-associated protein), Nedd4, and the TGF/BMP 
regulators Smurf1 and Smurf2.   
 The majority of E3s are of the RING (really interesting new gene) domain 
type, with at least 300 occurring in the human genome (Deshaies and Joazeiro, 
2009).  The RING domain is made up of cysteines and histidines spaced with 
other amino acids in an orientation that coordinates two zinc ions within the 
protein, and it is through this domain that E2s are recruited.  Among RING E3s, 
two classes exist: those in which the RING domain and substrate-binding domain 
are in the same protein, and those in which a generic RING domain protein 
serves as a subunit in a complex with other proteins, including a substrate-
binding protein.  Of the latter type, the most common are SCF complexes, in 
which an Rbx/Roc protein provides the RING domain for E2 binding, a cullin 
protein serves as a scaffold to bind the RING domain protein and a SKP1-related 
protein.  The substrate specificity in the SCF complex comes from the F box 
protein, which binds to SKP1 via its F box domain and the substrate through its 
substrate specificity site, bringing the substrate in proximity with the E2 and 
catalyzing ubiquitin conjugation. 
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 The F box is named for cyclin F, the first protein recognized with this 
domain (Kraus et al., 1994), but the first SCF complex described consists of 
Saccharomyces cerevisiae Cdc4 as the F box protein along with Cul1 and Skp1, 
an E3 complex that degrades Sic1 and other proteins (Feldman et al., 1997).  
The interaction between Cdc4 and Sic1 requires phosphorylation of Sic1, 
underlining a common theme among F box-substrate interactions in which the 
substrate must be somehow modified to improve the protein-protein interaction 
(Hao et al., 2007).  In another example, N-glycan modification is required to 
induce interaction of the SCFFbx2 ubiquitin ligase complex with its substrates in the 
ER-associated degradation (ERAD) pathway (Yoshida et al., 2002). 
 Despite the inordinately large number of F box proteins in the C. elegans 
genome (at least 200), few have been assigned functions or SCF partners.  One 
complicating factor is that, instead of one human SKP1, there are 21 C. elegans 
skr- (SKP1-related-) genes.  Of these, skr-1 and -2 are most closely related to 
human SKP1, as well as being adjacent in the C. elegans genome and 83% 
identical (Nayak et al., 2002; Yamanaka et al., 2002).  Injection of RNAi against 
skr-1 or -2 into the gonad of hermaphrodites led to the embryonic lethality of their 
progeny, due to cellular hyperplasia, a phenotype similar to cul-1 and lin-23 
mutants.  Because of the similarity between skr-1 and -2, it is unlikely that the 
RNAi is specific to either gene, making it impossible to determine which gene, or 
both, is responsible for this phenotype.  However, several lines of evidence 
suggest that skr-1 alone is relevant.  First, Yamanaka et al. report that skr-1 is 
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expressed ubiquitously from gastrulation to adulthood, while skr-2 is restricted to 
the gut (Yamanaka et al., 2002).  Second, Killian et al. report isolation of a 
deletion allele, tm2391, which deletes skr-1 but not skr-2 (Killian et al., 2008).  
This allele is embryonic lethal, with rare escapers displaying the SCFlin-23 
hyperplasia phenotype.  Finally, a hypomorphic missense allele of skr-1, sm151, 
fails to complement tm2391, giving further credence to the idea that tm2391 
affects only skr-1 (Killian et al., 2008). 
 While the ubiquitin-proteasome system has a role in virtually every 
process in cell biology, it is especially important for the regulation of apoptosis.  
The IAP (inhibitor of apoptosis) proteins, for example, are E3 ligases which are 
crucial for cell death control in vertebrates and Drosophila.  IAPs contain between 
one and three BIR (baculovirus IAP repeat) domains which are required for 
binding to caspases, as well as a C-terminal RING domain, through which IAPs 
mediate E2 recruitment.  The Drosophila protein DIAP1 acts as an inhibitor for 
caspases to keep them in check; DIAP1 mutants die during embryogenesis due 
to excessive cell death (Goyal et al., 2000; Lisi et al., 2000; Wang et al., 1999; 
Wilson et al., 2002).  In addition to BIR and RING domains, DIAP1 contains an 
IAP binding motif (IBM) which mediates its interaction with upstream IAP 
antagonists such as Reaper, Hid and Grim.  These pro-apoptotic molecules 
promote DIAP1 auto-ubiquitination and destruction by the proteasome with the 
help of UBCD1, inducing apoptosis (Ryoo et al., 2002; Wilson et al., 2002).  
DIAP1 is also controlled by N-end rule ubiquitination, but the physiologic role of 
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this modification remains an open question, as it has been reported to be both 
pro-apoptotic (Yokokura et al., 2004) and anti-apoptotic (Ditzel et al., 2003). 
 These results suggest that a pro-apoptotic protein like Reaper binds to 
DIAP1 to induce its auto-ubiquitination and degradation, releasing caspases from 
BIR domain binding and causing apoptosis.  However, deletion of the RING 
domain increases rather than decreases apoptosis suggesting that DIAP1 also 
contains anti-apoptotic function.  DIAP1 polyubiquitinates the caspases DRONC 
and drICE, inhibiting their activation either through a non-degradative pathway 
(Chai et al., 2003; Ditzel et al., 2008; Lisi et al., 2000; Ryoo et al., 2002; Ryoo et 
al., 2004; Wilson et al., 2002).  When DRONC is associated with Dark in the 
context of the apoptosome, however, DIAP1 appears to ubiquitinate it and induce 
its degradation (Shapiro et al., 2008).  Thus, the DIAP1 ubiquitin ligase is a 
complicated and central regulator of Drosophila apoptosis. 
In mammals, the E3 ligase XIAP prevents apoptosis when overexpressed 
and inhibits caspases-3, -7 and -9.  While the RING domain is not required for 
this inhibition in vitro (Deveraux et al., 1997), in vivo deletion of the RING results 
in mice predisposed to cancer and susceptible to pro-apoptotic insults (Schile et 
al., 2008).  This inhibition is the result of polyubiquitination of caspase-3 without 
accompanied degradation, suggesting that XIAP acts as an E3 for its function, 
not a simple caspase-binding inhibitor.  Another mammalian ubiquitin ligase 
complex implicated in apoptotic regulation is Bruce/Apollon, an E3 for caspase-9 
and Smac/Diablo (Bartke et al., 2004; Hao et al., 2004). 
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Ubiquitin modification is not only important for caspase control in 
apoptosis, but also in regulating caspase activation in non-death related contexts.  
One example is in the process of Drosophila sperm individualization, in which 
spermatids remove the bulk of their cytoplasm and organelles in a process that 
requires caspases but does not kill the cells (Arama et al., 2003).  By screening 
through a collection of male-sterile genetic mutants for defects in active caspase 
staining, a cullin3-based E3 ligase complex made up of Cul3Testis, Roc1b, and 
Klhl10 are required for caspase activation and sperm individualization.  dBruce, a 
giant BIR and UBC domain-containing protein that is also required for sperm 
viability, interacts with the substrate-specificity domain of Klhl10 and may be the 
relevant target for this E3 ligase (Arama et al., 2007).  The same screen yielded 
another mutant, ms771, which maps to a gene containing an F box, nutcracker.  
Nutcracker functions in an SCF complex with Cullin-1 and SkpA to regulate 
caspase activation in a unique way: it regulates the activity of proteasomes in the 
developing spermatid.  While there is no change in proteasome number in the 
nutcracker mutant, protein extracts from nutracker mutant testes showed a 
reduced ability to degrade a fluorogenic probe, suggesting a role for nutcracker in 
stimulating proteasome function (Bader et al., 2010). 
 In addition to direct regulation of apoptosis via caspases, the ubiquitin-
proteasome system has also been implicated in control of BCL2-family members.  
For example, Bim was reported to be ubiquitinated and degraded following 
ERK1/2 phosphorylation (Akiyama et al., 2003; Ley et al., 2003).  The Bid protein 
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must be cleaved to become active, as its N-terminal fragment obscures the pro-
apoptotic BH3 domain, located in the C-terminal fragment.  After cleavage, the N-
terminal inhibitory fragment is ubiquitinated and degraded, and this ubiquitination 
is unusual in that it occurs not on lysines but on serines, cysteines and 
threonines (Tait et al., 2007).  Zhong et al. reported that a HECT E3 ligase, 
HUWE, can bind to and polyubiquitinate MCL-1, an anti-apoptotic BCL2-like 
protein, and that HUWE contains a domain similar to the BH3 domain which 
promotes binding to MCL-1 (Zhong et al., 2005).  Finally, BCL2 has been 
reported to be degraded by the proteasome, as well as phosphorylated to 
regulate its activity.  Dimmeler et al. showed that human endothelial cells treated 
with TNF- degrade endogenous BCL2, and that this degradation can be 
inhibited by mutating lysines in the protein.  In this system, dephosphorylation 
increased BCL2 degradation, possibly through a MAP kinase module 
(Breitschopf et al., 2000; Dimmeler et al., 1999).  Phosphorylation of BCL2 was 
also reported to induce its proteasomal degradation, as is commonly the case 
with F box protein substrates.  The relevant E3 has not been identified, but Lin et 
al. reported that the phosphatase PP2A dephosphorylates BCL2 to prevent its 
degradation and that reduction of PP2A activity led to BCL2 phosphorylation and 
degradation (Lin et al., 2006). 
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DRE-1, a conserved F box protein 
 The mammalian homolog of dre-1, FBXO11, was first named VIT1, as its 
partial cDNA was isolated from melanocytes from patients with vitiligo (Le Poole 
et al., 2001).  In these cells, FBXO11 was expressed at lower levels than in 
control melanocytes.  An in silico approach was used to identify a putative protein 
arginine methyltransferase (PRMT) domain in the protein, although this domain is 
divergent from other PRMT proteins (Cook et al., 2006).  An in vitro methylation 
assay using immunoprecipitated PRMT9 isoform 4 (which lacks the F box) from 
HeLa cells, showed the capacity to methylate various histone and synthetic 
peptide substrates.  Abida et al. reported that FBXO11 can interact with p53 and 
induce its neddylation, and that this modification inhibits p53 transcriptional 
activity (Abida et al., 2007). 
 In developing mice, Fbxo11 protein was detected by 
immunohistochemistry starting at embryonic day 9.5, when staining was confined 
to the developing heart.  Later in development, expression was detected in liver, 
muscle, palatal epithelia, lung, kidney, adrenal gland, bone marrow, skin, 
hematopoietic cells, osteoblasts, spleen and middle ear.  In adults, of the tissues 
studied, staining occurred in alveolar macrophages, glomeruli and collecting 
tubules in the kidney, midbrain, heart and muscle (Hardisty-Hughes et al., 2006). 
 Two mutant mouse lines exist with lesions in mouse Fbxo11.  The Jeff 
mouse was isolated from an ENU screen for deafness and exhibits worsening 
deafness over time as a heterozygote, possibly due to chronic otitis media 
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(Hardisty et al., 2003).  Heterozygotes are 21% smaller than their wild-type 
littermates and have a mild craniofacial abnormality.  As homozygotes, all Jf/Jf 
animals died at birth or within a few hours because of respiratory difficulty and 
had upper eyelids open.  In addition, the craniofacial abnormalities were more 
severe, with facial clefting and clefting of the soft or hard palate.  A second 
mouse, Mutt, also contains a mutation in Fbxo11, and partially recapitulates the 
Jeff deafness, craniofacial abnormality and perinatal lethality phenotypes, but 
lacks otitis media and is likely a milder hypomorphic allele (Hardisty-Hughes et 
al., 2006). 
 Further studies by the same group focused on TGF- pathway proteins in 
the Jeff mouse because the palatal and eyes-open-at-birth (EOB) phenotypes 
have been observed in mutants in this pathway such as TGF--3, though not all 
mutants with these phenotypes are TGF--related (for example, Apaf-1 null mice 
have similar craniofacial and palatal fusion defects).  Tateossian et al. showed no 
effect of Fbxo11 mutation on expression of Fbxo11, TGF--3, TGF-RI or Smad 
4, but an increase in nuclear phospho-Smad2 in developing palates of Fbxo11 
homozygotes at E15.5 as assayed by immunohistochemistry, compared to wild-
type.  While there were no differences in proliferation as measured by Ki67 
staining in wild-type vs. Jeff palates, there was a modest but statistically 
significant reduction in the number of cells stained with an anti-cleaved caspase-
3 antibody (Tateossian et al., 2009). 
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 Characterization of the eyelid phenotype of Fbxo11 homozygotes showed 
a similar pattern of staining: no differences were observed in expression of 
Fbxo11, TGF--3, TGF-RI or Smad 4, but an increase in nuclear phospho-
Smad2 was seen at day 15.5.  Again, no differences were evident in Ki67 
staining, but there was a significant reduction in the level of cleaved caspase-3 in 
Fbxo11 homozygotes.  Smad2/+; Fbxo11/+ animals showed a significant lethality 
defect (66% died soon after birth), as well as respiratory difficulty.  
Immunoprecipitation of Fbxo11 failed to detect an interaction with Smad2 or p53 
(Tateossian et al., 2009). 
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Chapter 2:  Genetic control of tail-spike cell fusion and tail 
morphogenesis 
 
2.1 Background 
As reported by Sulston, the tail-spike cell is born as two precursor cells, the 
sisters of the hyp10 precursors, which fuse during embryogenesis to form a 
single syncitium, differentiate by extending a thin microtubule-containing process 
posteriorly, and die during late embryogenesis (Fig. 3). 
 
 
Fig. 3.  The life and death of the tail-spike cell. 
The tail-spike cell lives for ~340 minutes, and during that time undergoes fusion 
and differentiation.  Reproduced from (Maurer et al., 2007). 
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In C. elegans, 300 out of 959 nuclei of the somatic cells are parts of 
syncitia.  In addition, because of the stereotyped nature of C. elegans 
development, the cells which fuse have the same partners and fuse predictably.  
Two genes have been isolated from screens for defective fusion, eff-1 and aff-1, 
which are conserved in other nematodes but do not have homologues in other 
organisms.  eff-1 was isolated from a screen in which animals expressing an 
adherens junction protein labeled with GFP (AJM-1::GFP) failed to fuse cells that 
normally fuse.  eff-1 mutants fail to fuse all 43 epidermal cells that are 
programmed to fuse during embryogenesis, and also show defects in fusions 
post-embryonically (Mohler et al., 2002).  Mohler et al. reported that eff-1 mutants 
have abnormalities in tail-spike morphogenesis, as well as misshapen male tails 
in which the tail-spike persists inappropriately.  It was later shown that eff-1 is 
required in both fusing cells to induce fusion, and that expression of eff-1 was 
sufficient to induce fusion of heterologous insect cells (Podbilewicz et al., 2006). 
 While the majority of fusions require eff-1, certain cells remain competent 
to fuse in eff-1 mutants, including the anchor cell, which fuses during normal 
vulval development to open the vulva for egg-laying.  Sapir et al. screened for 
egg-laying defective animals and examined anchor cell fusion to identify a 
mutation in the aff-1 gene (anchor cell fusion failure-1) (Sapir et al., 2007).  aff-1 
is structurally similar to eff-1, and, like eff-1, can induce fusion when expressed 
ectopically in C. elegans as well as when expressed in heterologous cells. 
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 While the work described above defined the genes necessary for many 
fusions in C. elegans development, the gene(s) required for tail-spike cell fusion 
were not known.  In addition, the role of fusion in regulation of cell death has not 
been investigated. 
 
2.2  Results 
aff-1 is required for tail-spike cell fusion 
We wondered whether fusion played a role in tail-spike cell death.  To 
address this question, we first tested whether aff-1 (anchor cell fusion failure-1), a 
newly-described fusogen that is required for fusion of the anchor cell during 
vulval development as well as for the fusions of a number of other cell pairs, was 
required for tail-spike cell fusion.  A previously-isolated fusogen, eff-1 (epithelial 
fusion failure-1) was found by Carine Maurer to have no role in tail-spike cell 
fusion (Maurer, PhD thesis).  aff-1, however, was required for tail-spike cell 
fusion, as we observed two healthy but unfused cells in aff(tm2214);ced-
3(n717);nsIs25 animals.  We conclude that aff-1, but not eff-1, is required for tail-
spike cell fusion. 
 For further evidence that aff-1 is involved in tail-spike cell fusion, we tested 
whether a transcriptional reporter for aff-1 was expressed in the tail-spike cell.  
Indeed, the 4.5 kb genomic fragment upstream of the aff-1 start codon drove 
GFP expression within the tail-spike cell in ced-3(n717) animals (Fig. 4).  GFP 
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was also expressed in other cells throughout the animal, but, importantly, not in 
hyp10. 
 
 
 
 
 
 
  
 
Fig. 4.  aff-1pro::gfp is expressed in the tail-spike cell. 
Fluorescence images of tails of two representative L1 ced-3(n717) animals in 
which GFP expression is evident in the tail-spike cell. 
 
 
 
 
 
 
 
 
 
 Having established aff-1 as the relevant fusogen for the tail-spike cell, we 
could address whether fusion was required for death.  In aff-1(tm2214);nsIs25 
animals, 0% of L1s had surviving tail-spike cells, showing that unfused cells are 
fully capable of undergoing programmed cell death. 
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Tail-spike cell non-fusion affects tail morphogenesis 
While examining aff-1(tm2214) mutants, we noticed an unusual tail 
morphology defect: a large number of L1s had forked tails.  Quantification of this 
serendipitous finding showed that 78% of aff-1(tm2214) L1s had forked tails, 
while 0% of N2 L1s and 0% of eff-1(hy40) L1s had forked tails (eff-1 animals 
frequently had rounded tail tips or tail tips with knobs attached) (Fig. 5).  The 
percentage of animals with forked tails in aff-1(tm2214) may be an underestimate 
because we observed some animals in which one fork was significantly smaller 
or broken, suggesting that the fork may not always be even and the smaller half 
may be lost during the animals life. 
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Fig. 5.  aff-1(tm2214) but not eff-1(hy40) or wild-type animals have forked 
tail-tips. 
Top: Quantification of the percentage of animals with forked tails, as assessed by 
DIC microscopy (n>100 for each genotype). 
Bottom:  Representative images from two L1 aff-1(tm2214) animals, showing the 
forked tail defect common in this mutant. 
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Given that Sulston had postulated that the tail-spike cell process forms a 
scaffold for hyp10 morphogenesis, and given the electron microscopic (EM) 
results showing a microtubule core within the tail-spike cell that persists after its 
death, we wondered whether the aff-1(tm2214) forked tail phenotype might be 
related to the tail-spike cells remaining unfused.  In examining aff-1(tm2214);ced-
3(n717);nsIs25 animals more carefully, we were able to identify many animals in 
which each unfused tail-spike cell had generated a process extending into the 
posterior of the animal.  Thus, it is likely that, with two microtubule-containing 
processes within itself instead of one, hyp10 is improperly patterned in aff-
1(tm2214) animals, and the forked tail phenotype results.  While these results are 
not proof that the tail-spike cell fusion defect is responsible for the forked tail 
phenotype (a tail-spike cell-specific rescue of the aff-1 mutation would be 
necessary to prove this, an experiment that is rendered impossible because we 
lack an early tail-spike cell-specific promoter), the correlation between two 
processes and forked tails is striking evidence to support this idea. 
 
2.3  Conclusion 
These results lend support to the Sulston model in which the tail-spike 
cells major, or possibly sole, function is to extend a microtubule-laden process 
posteriorly during embryogenesis to direct proper hyp10 morphogenesis and tail-
tip shape.  Presumably, when this function has been served, the cell is no longer 
necessary for the organism, and thus undergoes programmed cell death.  In the 
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context of failed tail-spike cell fusion as in aff-1 mutants, each unfused tail-spike 
cell appears able to direct morphogenesis of a separate tail-spike, leading to a 
forked tail.  Thus, proper tail-spike cell morphogenesis in the form of a fused cell 
with one process is crucial to building the elegant C. elegans tail-spike. 
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Chapter 3:  Cloning and characterization of a novel regulator of 
programmed cell death 
 
3.1  Background 
The tail-spike cell as a system for uncovering apoptotic regulators 
 A great many screens have been performed to find regulators of 
apoptosis, and these screens have defined the core apoptotic machinery to 
include egl-1, ced-9, ced-4 and ced-3 in a linear pathway. 
 
egl-1      ced-9  ced-4       ced-3  Apoptosis 
(BH3-only)    (BCL2)          (Apaf1)    (caspase) 
 
 
With these screens for global cell death genes saturated, we turned to studying 
individual cells as a way to better understand the mechanisms of apoptosis.  Of 
the individual cells that undergo programmed cell death in C. elegans, we chose 
to study the tail-spike cell for two major reasons.  First, the tail-spike cell is one of 
only a few cells that is long-lived during C. elegans development before 
undergoing apoptosis.  While most cells die within 20 minutes of being born, the 
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tail-spike cell lives 10 times as long, and during that time differentiates by 
extending a process posteriorly.  Thus, it more closely resembles the deaths of 
mammalian cells, which die after differentiation.  Second, and most importantly, 
the genetic control of tail-spike cell death is unique.  While egl-1 is required for 
virtually all other deaths in the worm, in the tail-spike cell it is dispensable for 
death.  Worms carrying a non-functional egl-1 gene have a persistent tail-spike 
cell 30% of the time.  In other words, in 70% of animals, the tail-spike cell can be 
specified for death and execute that fate in the complete absence of egl-1 activity 
(Fig. 6).  With ced-3 and ced-4 being completely required for tail-spike cell death, 
we recognized that the tail-spike cell represents an ideal system for uncovering 
new regulators of caspase activation: in the absence of egl-1, some other 
gene(s) must be responsible for activating ced-3 and ced-4.  We set out to 
identify these gene(s). 
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Fig. 6.  Tail-spike cell death requires ced-3 and ced-4 but egl-1 is 
dispensable for death. 
Percentage of animals with a surviving tail-spike cell in ced-3(n717), ced-
4(n1162) and egl-1(n1084n3082) strains.  All strains contain the nsIs25 
transgene to mark the tail-spike cell (n>100 for each).  Reproduced from (Maurer 
et al., 2007). 
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3.2  Results 
 
 
A forward genetic screen for regulators of tail-spike cell death 
 To identify the gene(s) acting in place of egl-1 in the tail-spike cell to 
regulate apoptosis, Carine Maurer performed a forward genetic screen on 
animals carrying the ced-3pro::gfp integrated transgene (nsIs25) which marks the 
tail-spike cell.  She mutagenized nsIs25 animals with ethyl methanesulfonate, 
screened the F2 progeny for animals with surviving tail-spike cells and isolated 8 
putative mutants, ns16, ns17, ns18, ns19, ns38, ns39, ns40 and ns41.  In 
addition to looking for animals in which the tail-spike cell survived, she focused 
on mutants that lacked a global cell death defect as a way to avoid alleles of ced-
3 and ced-4.  We checked these 8 mutants for survival of the tail-spike cell: 5/8 
had <1% tail-spike cell survival, and because of the low penetrance of the defect, 
chose not to pursue these mutants (Fig. 7).  Of the remaining 3, ns38 had a 
significant global cell death defect (7.2 extra cells in the pharynx, as assayed by 
Shai Shaham), and ced-3 failed to complement this defect.  We conclude that 
ns38 is an allele of ced-3.  The remaining two mutants, ns39 and ns40, fail to 
complement each other, and thus likely represent lesions in distinct genes.  19% 
of ns40;nsIs25 animals have a surviving tail-spike cell. 
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Fig. 7.  Tail-spike survival in mutants isolated from a forward genetic 
screen. 
Percentage of animals with a surviving tail-spike cell in strains with the indicated 
genotypes.  ns16, ns17, ns18 and ns19 contain the nsIs23 transgene while ns38, 
ns39, ns40 and ns41 contain the nsIs25 transgene to mark the tail-spike cell 
(n>100 for each). 
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 The tail-spike cell survives inappropriately in ~79% of animals carrying the 
ns39 mutation, compared to 0% in wild-type animals.  In addition, the surviving 
tail-spike cell in ns39;nsIs25 animals expresses ced-3pro::gfp, indicating that 
ced-3 transcription is intact and placing ns39 in a different class from pal-1-like 
mutants in which tail-spike cell death is prevented by lack of ced-3 transcription.  
In ns39 mutants the tail-spike precursor cells fuse properly and the cell extends a 
process posteriorly, making the surviving tail-spike cells in this strain 
indistinguishable from those in ced-3 or ced-4 mutant strains.  
 The result that the tail-spike cell survives inappropriately in 79% of animals 
implies that it is born and dies appropriately in the remaining animals.  To test 
this assumption, I crossed the ns39 mutation to the ced-5(n1812) background, in 
which apoptotic corpses are not engulfed, making their identification by DIC 
microscopy easy.  In this background, the tail-spike cell survived 71% of the time 
and in all of these animals no corpse was evident in the tail (Fig. 8).  In 29% of 
animals, a corpse was present in the proper position that harbored residual GFP 
expression, and no other cells in the area expressed GFP.  Finally, there were 
zero animals in which neither a surviving cell nor a corpse were present, or both 
were present.  Thus, the reason for no tail-spike cell being evident in ns39;nsIs25 
animals is that it has died, not that it was never generated, or that it was alive but 
the ced-3pro::gfp marker had not been activated. 
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Fig. 8.  The ns39 mutation blocks tail-spike cell death but does not alter 
cell fate. 
The status in L1 animals of the tail-spike cell was assessed in wild-type, ced-
5(n1812) engulfment defective, and ns39; ced-5(n1812) backgrounds.  In wild-
type animals, the cell always dies and the corpse is cleared.  In ced-5(n1812) 
animals, the cell always dies and the corpse is evident in 96% of animals.  In 
ns39; ced-5(n1812) animals, the cell survives in 71% of animals and can be seen 
as a healthy cell; in the remaining 29% of animals, the cell dies and its corpse 
can be identified (n>100 for each). 
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 Because these observations about the ns39 mutation are consistent with it 
blocking ced-3 caspase activation in the tail-spike cell to prevent apoptosis, I 
decided to pursue this mutant further. 
 
 
The ns39 mutation maps to the dre-1 gene 
 After backcrossing five times, I used standard SNP-mapping techniques to 
map the ns39 mutation to a region on Chromosome V between -0.183 and 0.109 
MU.  Within this region, several genes were reported to have an egg-laying 
defect, as was observed in the ns39 strain.  Of these, I sequenced the dre-1 (daf-
12-redundant-1) gene and identified a C to T change, consistent with this being 
an EMS-induced mutation.  This lesion is predicted to induce a serine to leucine 
missense mutation at position 275 of the protein (based on the “new” cDNA, see 
below). 
 dre-1 was named by Adam Antebis group who were studying the effects 
of daf-12 on developmental timing.  They isolated several alleles of dre-1, 
including dh99 and dh279.  I tested whether these alleles shared the tail-spike 
cell death phenotype of ns39 by crossing them to the nsIs25 marker.  Indeed, 
both of these independently isolated alleles showed tail-spike cell death defects, 
of 12 and 2%, respectively, consistent with dre-1 being the gene responsible for 
the ns39 defect (Fig. 9). 
 37 
 
 
 
 
 
Fig. 9.  Mutations in dre-1 block tail-spike cell death. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 To further demonstrate that dre-1 is the relevant gene for tail-spike cell 
death, I did a complementation test between two independently isolate alleles of 
dre-1 – ns39 and dh99.  25% of animals with the genotype ns39/dh99 had a 
surviving tail-spike cell, showing that ns39 and dh99 fail to complement each 
other and lending further support to the idea that dre-1 controls tail-spike cell 
death (note that this percentage may be an underestimate of tail-spike cell 
survival in these animals as the nsIs25 marker was heterozygous in all animals 
scored) (Fig. 10).  In the course of this cross, I also generated animals 
heterozygous for either ns39 or dh99; none of these animals had a surviving tail-
spike cell, demonstrating that both mutations are recessive with respect to tail-
spike cell death.  In addition, I found that ns39/gk857 animals (gk857 is a deletion 
that removes 599 bp of the dre-1 cDNA from position 155 to 753) are mostly 
inviable.  The few animals of this genotype I was able to produce died as L1 
larvae (5 animals).  None of these animals had a surviving tail-spike cell, though 
they were very sick and died soon afterwards. 
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Fig. 10.  dre-1(dh99) and dre-1(ns39) fail to complement each other with 
respect to the tail-spike cell death defect. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 If dre-1 is involved in promoting tail-spike cell death, then ectopically 
expressing wild-type dre-1 in the tail-spike cell of ns39 mutants should induce 
apoptosis.  I used several methods to rescue the ns39 phenotype. 
 First, I injected two overlapping fosmids that include the dre-1 sequence 
into the ns39 mutant.  WRM067bH07 contains 31.7 kb of genomic sequence, 
including 13.5 kb upstream of the “old” dre-1 ATG (see below) and 13.8 kb 
downstream of the stop codon.  This fosmid rescued the tail-spike cell death 
defect fully, giving 2% survival in transgenic animals (Fig. 11).  WRM0637aG11 
contains 33.7 kb of genomic sequence, including 21.1 kb upstream of the “old” 
dre-1 ATG (see below) and 8.2 kb downstream of the stop codon. This fosmid 
also rescued the tail-spike cell death defect, giving 7 and 13% survival in two 
independent lines.  Thus, the information required for rescue is contained within 
these ~30 kb of genomic sequence. 
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Fig. 11.  Two fosmids containing the dre-1 locus rescue the tail-spike cell 
death defect in dre-1(ns39) animals. 
Percent of animals with a surviving tail-spike cell in wild-type, dre-1(ns39), and 
dre-1(ns39) + indicated fosmid (n>100 for each).  All strains contain the nsIs25 
transgene to mark the tail-spike cell. 
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 The overlapping region within these two fosmids contains dre-1, acs-1 
(fatty acid CoA synthetase-1), F46E10.11 (a predicted non-coding RNA), and 
twk-10 (a potassium channel).  To determine whether dre-1 is in fact the relevant 
gene, I attempted to rescue the ns39 phenotype with the dre-1 cDNA.  Initial 
attempts to rescue using the cDNA reported by Adam Antebis group (Fielenbach 
et al.) driven by 4.4 kb of genomic sequence upstream of the ATG failed to 
rescue, and Fielenbach et al. reported difficulty in rescuing with the cDNA and 
instead only rescued with a YAC and a 15 kb genomic fragment. 
 We wondered whether the reported cDNA was incomplete.  Examination 
of the sequence upstream of the ATG identified a putative splice donor site ~8kb 
upstream.  In addition, Aceview.org reported an incomplete cDNA clone using 
this ATG spliced to the reported sequence that is in frame.  To test whether this 
putative exon was in fact part of the dre-1 cDNA I performed PCR on cDNA 
isolated from mixed stage worms graciously provided by Maya Tevlin.  A forward 
primer beginning with the “new” ATG and a reverse primer in the “old” first exon 
produced a band of the proper size if this “new” exon was in fact spliced to the 
“old” cDNA (Fig. 12).  Sequencing of this product revealed an in-frame splice 
junction.  In addition, PCR using a forward primer corresponding to the SL1 splice 
leader sequence and a reverse primer within the “new” first exon produced a 
product that was the expected length and sequence, showing that this ATG is in 
fact utilized in the worm and that it is SL1 spliced.  In addition, SL1 splicing 
occurs to the “old” dre-1 cDNA, as previously reported (Fielenbach et al.) but it is 
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unclear whether this transcript is in fact biologically relevant. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12.  Exon structure of the “old” versus “new” dre-1 cDNA. 
The new cDNA (bottom) includes an exon 8 kb upstream of the originally 
reported start codon.  SL1 splicing was detected in both forms. 
 
 
 
 
 
 
 
 The new cDNA is 258 bp longer, and converts the 5UTR from the old 
cDNA into coding sequence, producing a protein that is 86 amino acids longer.  
This sequence is conserved in C. briggsae, though it yields no new domains and 
is not conserved in other organisms. 
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 Using this new dre-1 cDNA in rescue experiments proved successful.  A 
construct consisting of the new dre-1 cDNA under the aff-1 promoter and 
including the dre-1 3UTR rescued the dre-1(ns39) tail-spike cell death defect.  In 
3 independent lines, tail-spike cell survival was reduced from 79% to 11, 22 and 
46% (Fig. 13).  This experiment warrants two conclusions.  First, this shows that 
loss of dre-1 is responsible for the ns39 phenotype and establishes dre-1 as a 
regulator of apoptosis in the tail-spike cell.  Second, because the aff-1 promoter 
expresses in the tail-spike cell but not its sister, hyp10, this experiment shows 
that dre-1 acts cell autonomously to induce tail-spike cell death. 
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Fig. 13.  Expression of the DRE-1 cDNA under the aff-1 promoter rescues 
the dre-1(ns39) tail-spike cell death defect. 
Percent of animals with a surviving tail-spike cell in wild-type, dre-1(ns39), and 
dre-1(ns39) + aff-1p::DRE-1 transgenes (n>100 for each).  The aff-1 promoter 
expresses in the tail-spike cell but not hyp10.  All strains contain the nsIs25 
transgene to mark the tail-spike cell. 
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 In addition, we also expressed the dre-1 cDNA under the dpy-30 
ubiquitous promoter (Fig. 14).  This construct also rescued the dre-1(ns39) 
defect, albeit less well, possibly because this promoter is not very strong (Shai 
Shaham, personal communication). 
 
 
 
 
 
Fig. 14.  Expression of the DRE-1 cDNA under the dpy-30 ubiquitous 
promoter rescues the dre-1(ns39) tail-spike cell death defect. 
Percent of animals with a surviving tail-spike cell in wild-type, dre-1(ns39), and 
dre-1(ns39) + dpy-30p::DRE-1 transgenes (n>100 for each).  All strains contain 
the nsIs25 transgene to mark the tail-spike cell. 
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 Having established that dre-1 is required cell autonomously for tail-spike 
cell death, I investigated its expression pattern.  Fielenbach et al. had described 
dre-1 as being expressed in many cells during embryogenesis, especially 
epidermal-like cells (Fielenbach et al., 2007).  A 4 kb promoter construct taken 
from intron 1 of the dre-1 gene expressed in many cells, including the tail-spike 
cell (Fig. 15).  The tail-spike cell expression was confirmed by co-expressing RFP 
under the control of the ced-3 promoter which marks the tail-spike cell.  Thus, 
dre-1 is expressed and acts in the tail-spike cell to control death. 
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Fig. 15.  dre-1 is expressed in the tail-spike cell. 
A ~4kb promoter fragment from intron 1 of the dre-1 locus drives GFP expression 
in the tail-spike cell.  Two representative L1 animals are shown expressing ced-
3p::NLS-RFP to mark the tail-spike cell, dre-1p::NLS-GFP to mark dre-1-
expressing cells and the merged image to show their overlap in the binucleate 
tail-spike cell.  Arrows point of the tail-spike cell.  Both animals contain the ced-
3(n717) mutation to allow visualization of the tail-spike cell in larvae. 
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dre-1 interacts genetically with core cell death pathway genes 
 Our results to this point suggest that dre-1 acts as a pro-apoptotic 
molecule in the tail-spike cell to regulate developmental cell death.  If this is the 
case, we would expect that it would interact genetically with alleles of the core 
apoptotic machinery, and the result might be a synergistic increase in tail-spike 
cell survival.  As an example, combining a weak ced-3 allele (n2436) with the 
ced-9(n1950) gain-of-function allele leads to a significant rise in the number of 
animals with a surviving tail-spike cell; ced-3(n2436) animals have 59% 
inappropriate survival, ced-9(n1950) animals have 3% survival, and ced-
3(n2436);ced-9(n1950) animals exhibit 93% tail-spike cell survival (Fig. 16).  
Thus, weakening two parts of the core apoptotic machinery – EGL-1s ability to 
inhibit CED-9 and the caspases ability to dismantle the cell – leads to a 
synergistic increase in survival.  We wondered whether a similar effect would 
occur using dre-1 alleles.  
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Fig. 16.  Combining weak loss-of-function mutations in two apoptotic 
regulators leads to a synergistic increase in tail-spike cell survival. 
Reproduced from (Maurer et al., 2007). 
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 Combining ced-3 and dre-1 alleles does in fact create a synergistic 
increase in the cell death defect.  For example, while ced-3(n2427);nsIs25 
animals have 0% tail-spike cell survival, and dre-1(dh99);nsIs25 animals 12%, 
dre-1(dh99);ced-3(n2427);nsIs25 animals have 46% tail-spike cell survival (Fig. 
17).  Thus, dre-1(lf) mutants are a sensitized background with respect to tail-
spike cell death, and in the presence of a weakened caspase, the cell survives at 
a greatly increased rate. 
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Fig. 17.  dre-1; ced-3(weak) double mutants display a synergistic increase 
in tail-spike cell survival. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
 
 
 53 
 Only one weak ced-4 allele exists, n3158, and a similar analysis showed a 
similar synergistic effect (Fig. 18). 
 
 
 
 
 
Fig. 18.  dre-1; ced-4(weak) double mutants display a synergistic increase 
in tail-spike cell survival. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 The ced-9(n1950) gain-of-function allele disrupts EGL-1 binding to CED-9, 
creating a constitutive inhibitor of cell death.  While this allele has, on its own, a 
relatively weak effect on tail-spike cell death, it displays a synergistic increase in 
tail-spike cell survival in the absence of full dre-1 activity (Fig. 19). 
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Fig. 19.  dre-1; ced-9(n1950) double mutants display a synergistic increase 
in tail-spike cell survival. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 Carine Maurer showed that egl-1 is dispensable for tail-spike cell death: in 
egl-1(null) mutants, the tail-spike cell dies in 70% of animals.  This result raises 
the question of what is substituting for egl-1 in the tail-spike cell to regulate 
caspase activation?  Could dre-1 be responsible for this activity?  If so, we would 
again expect a synergistic effect of combining an egl-1 mutation with dre-1 
mutations.  This is in fact what we see, as double mutant combinations show 
increased tail-spike cell survival (Fig. 20). 
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Fig. 20.  dre-1; egl-1(null) double mutants display a synergistic increase in 
tail-spike cell survival. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 These results showing that dre-1 mutations enhance mutations in pro-
apoptotic genes are consistent with dre-1 acting as a bona fide apoptotic 
regulator in the tail-spike cell.  We wondered whether ced-9, the major anti-
apoptotic molecule in C. elegans, would also interact genetically with dre-1.  
Constructing strains with the ced-9(n2812) allele is complicated by the fact that 
ced-9(n2812) homozygotes are inviable due to excess cell death; thus, a weak 
ced-3 allele must always be present in the background to bypass this defect.  
Comparing dre-1(ns39);ced-3(n2427) animals to ced-9(n2812);dre-1(ns39);ced-
3(n2427) animals shows a marked decrease in cell survival, with the levels closer 
to ced-3(n2427) alone (Fig. 21).  This experiment demonstrates an epistatic 
relationship between ced-9 and dre-1 with respect to tail-spike cell death: in the 
absence of ced-9, dre-1 status is largely irrelevant. 
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Fig. 21.  dre-1 acts upstream of, or in parallel to, ced-9. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 This result tells us several things.  First, it shows that ced-9, despite egl-
1s minor role in tail-spike cell death, retains its anti-death function in this cell.  
Before we uncovered dre-1s function in tail-spike cell death, the only role for 
ced-9 was evident in egl-1(n1084n3082);ced-9(n2812);ced-3(n2427) animals, 
where the cell dies 100% of the time and which shows that egl-1 acts through 
ced-9 to promote death, albeit in a minor role.  Second, this result shows that 
dre-1 acts upstream of, or in parallel to, ced-9 to control tail-spike cell death.  
Third, it shows that dre-1 may have a role as a controller of cell death through a 
different pathway, as 20% of animals retain a surviving tail-spike cell in this 
strain.  Thus, even in the absence of ced-9, dre-1 still affects cell death. 
 The homeodomain transcription factor pal-1 is required for tail-spike cell 
death as a transcriptional activator of ced-3 just prior to death (Maurer et al., 
2007), which, given that dre-1 appears to act upstream of or in parallel to ced-9, 
would suggest that pal-1 should be epistatic to dre-1.  pal-1;dre-1 double mutants 
support this prediction, as they show diminished ced-3pro::gfp expression (Fig. 
22).  These results are consistent with dre-1 acting upstream of or in parallel to 
ced-9 and pal-1 activation of ced-3 transcription being far downstream in the 
cascade of tail-spike cell death. 
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    dre-1(dh99)    dre-1(dh99); 
         pal-1(ns114) 
 
 
Fig 22.  pal-1 is epistatic to dre-1 with respect to ced-3 transcription. 
One second exposures of surviving tail-spike cells in dre-1(dh99) and dre-
1(dh99);pal-1(ns114) animals.  Note that GFP expression is significantly dimmer 
in the pal-1 mutant, as would be expected if it is acting downstream to regulate 
ced-3 transcription.  Both animals contain the nsIs25 ced-3pro::gfp transgene to 
visualize ced-3 transcription. 
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 Because of pal-1s effects on ced-3 transcription, pal-1 mutants also 
display a tail-spike cell death defect, with 30% of animals showing a surviving 
tail-spike cell in pal-1(ns114) animals.  Scoring tail-spike cell survival in these 
animals is complicated by the fact that the ns114 mutation reduces ced-3pro::gfp 
expression in the tail-spike cell, making it difficult to discern whether the tail-spike 
cell has survived.  The reduced ced-3pro::gfp is incompletely penetrant, however, 
making it possible to see the tail-spike cell in some animals, with the caveat that 
this is an underestimate of tail-spike cell survival.  Despite that limitation, we were 
able to see an increase in tail-spike cell survival when combining pal-1 and dre-1 
mutants, consistent with both having partial effects on tail-spike cell death (Fig. 
23). 
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Fig. 23.  dre-1; pal-1(ns114) double mutants display an increased tail-spike 
cell death defect. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each). These numbers are an underestimate because they 
do not count animals in which the pal-1 mutation completely abolished ced-
3pro::gfp transcription in the tail-spike cell, which we are unable to score.  All 
strains contain the nsIs25 transgene to mark the tail-spike cell. 
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dre-1 does not regulate pharyngeal cell death 
 Having established dre-1 as a regulator of apoptosis in the tail-spike cell, 
we wondered whether it plays a similar role in other cells.  To address this, we 
used the pharynx assay, in which the number of cells present in the anterior 
pharynx is counted under DIC microscopy.  In animals with mutations in the core 
apoptotic machinery, as many as 14 extra cells accumulate in the anterior 
pharynx, and this assay allows quantification of the global cell death defect.  
These assays were performed by Shai Shaham. 
 First, we addressed whether dre-1(ns39) animals had extra cells in the 
pharynx (Table 1).  As we expected from initial experiments by Carine Maurer 
described above in which mutants from the screen were secondarily screened by 
checking for a global cell death defect, dre-1(ns39) animals had no extra cells in 
the pharynx.  This result is also unsurprising considering that dre-1 was not 
isolated in any screens for global cell death defects based on the pharyngeal cell 
death assays. 
 We looked for other evidence that dre-1 plays a role in pharyngeal cell 
death by asking whether the dre-1(ns39) mutation could enhance the death 
defect of weak ced-3 alleles:  dre-1 might have a supporting role in promoting 
death which might only be uncovered in the setting of weakened caspase activity.  
However, dre-1(ns39);ced-3(n2436) animals did not show an increased number 
of cells in the pharynx suggesting that dre-1 may not play a part in these cell 
deaths (Table 1).  As a parallel experiment, we tested whether egl-
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1(n1084n3082)/+; dre-1(n39)/+ animals had extra cells in the pharynx, as our tail-
spike cell data suggest that dre-1 acts upstream of ced-9, in place of egl-1.  
Again, no extra cells were found in the pharynxes of these animals, making it 
unlikely that dre-1 is a major player in pharyngeal cell death (Table 1).  Thus, we 
conclude that dre-1 is required for tail-spike cell, but not pharyngeal cell death. 
 
 
 
Genotype # extra cells 
ced-3(n2436) 4.2 
dre-1(ns39) 0 
ced-3(n2436); 
dre-1(ns39) 
3.7 
dre-1(ns39)/+;  
egl-1(n1084n3082)/+ 
0 
 
 
Table 1.  The dre-1(ns39) mutation does not affect cell death in the 
pharynx. 
Global cell death was assessed in the anterior pharynx in ced-3(n2436), dre-
1(ns39), ced-3(n2436);dre-1(ns39) double mutants and dre-1(ns39)/+;egl-
1(n1084n3082)/+ heterozygotes.  No effect was seen in dre-1 mutants (counts 
performed by Shai Shaham). 
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C05C8.6, a BTB/POZ domain protein, may play a minor role in tail-spike cell 
death 
 A high-throughput yeast two-hybrid screen of thousands of C. elegans 
proteins showed that DRE-1 interacts with C05C8.6 in this assay (Li et al., 2004).  
C05C8.6, a BTB/POZ domain protein, remains uncharacterized, but the fact that 
it contains a BTB domain was intriguing to us, considering the role that BTB 
domain-containing proteins have in the ubiquitin-proteasome system.  In addition, 
Li et al. reported that C05C8.6 interacts with itself; GLY-4, a predicted UDP-
galNAc-ase; GST-24, a glutathione transferase; RAD-26, a helicase; and 
F52B11.1, a PHD Zn-finger protein.  Alleles are available for C05C8.6, gly-4 and 
gst-24, and we tested whether any of these had an effect on tail-spike cell death. 
 On their own, mutations in none of C05C8.6, gly-4 or gst-24 blocked tail-
spike cell death, with 1%, 1% and 1.5% of animals having an inappropriately 
surviving tail-spike cell, respectively (Fig. 24).  We tested whether these 
mutations had any effect on tail-spike cell death in the context of the dre-1(ns39) 
mutation.  C05C8.6(tm3719) had a slight suppressive effect on tail-spike cell 
death in the C05C8.6(tm3719); dre-1(ns39) double mutant: 59% vs. 79% 
inappropriate survival (Fig. 24).  This suppression could suggest that C05C8.6 
acts downstream of, or in parallel to dre-1 to regulate tail-spike cell death, but 
such a weak effect is difficult to interpret, and could also be due to other 
mutations in the background.  gly-4(ok2943) enhanced tail-spike cell survival 
slightly when combined with the dre-1(ns39) mutation, increasing survival from 
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79% to 87% (Fig. 24).  Again, this weak enhancement of tail-spike cell survival is 
difficult to interpret, although the fact that dre-1 contains three CASH domains 
reported to be involved in carbohydrate binding makes gly-4 an intriguing gene.  
gst-24(ok3042) had no significant effect on the dre-1(ns39) mutant, with tail-spike 
cell survival of 70% vs. 79%.  We conclude that C05C8.6 may play a minor role 
in tail-spike cell death, and gly-4 may as well, while gst-24 is unlikely to be 
involved in this process. 
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Fig. 24.  C05C8.6 and its putative interacting partners play a minor or 
negligible role in tail-spike cell death. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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Tail-spike cell death is not affected by heterochronic genes but may be 
subtly controlled by a microRNA 
 The dre-1 3UTR contains several putative microRNA binding sites as 
predicted by various online tools.  mir-2 and mir-71 have high scores for 
complementarity and alleles exist for both of these genes.  To test whether mir-2 
or -71 have a role in tail-spike cell death, we crossed both of these mutants to the 
tail-spike cell GFP reporter, nsIs25.  Neither mir-2;nsIs25 nor mir-71;nsIs25 
animals had any evidence of tail-spike cell survival (Fig. 25).  We also tested 
whether mir-71 interacted genetically with dre-1 in any way.  Surprisingly, mir-
71;dre-1(ns39);nsIs25 animals had an enhanced tail-spike cell death defect, 
suggesting that mir-71 may have a weak pro-death effect that is only unmasked 
in the context of the dre-1 mutant. 
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Fig. 25.  A mir-71 mutation enhances the tail-spike cell death defect in dre-
1(ns39) animals. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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  dre-1 was isolated from a screen for enhancers of a daf-12 mutations 
effect on heterochronic phenotypes (distal tip cell migration and seam cell 
fusion).  The genes lin-4, lin-46, lin-29 and lin-28 have been implicated in these 
processes and thus we wondered whether there was a connection between tail-
spike cell death and any of these genes.  Crossing each to the nsIs25 tail-spike 
cell marker showed that none of the resulting strains had tail-spike cell death 
defects (Fig. 26).  With this result, in concert with the fact that all heterochronic 
phenotypes are post-embryonic while tail-spike cell death occurs during 
embryogenesis, we conclude that dre-1s role in regulating tail-spike cell death is 
independent of these heterochronic pathways. 
 
 72 
 
 
 
 
 
 
 
Fig. 26.  dre-1 does not act in a heterochronic pathway to regulate tail-
spike cell death. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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3.3  Conclusions 
 The major draw of studying the tail-spike cell is that, while its death 
requires ced-3 caspase activation through ced-4, egl-1 plays a relatively minor 
role in controlling ced-3 activation.  Thus, the power of C. elegans genetics can 
be used to identify novel genes that influence caspase activation, and act in egl-
1s stead. 
 Several lines of evidence show that dre-1 is a bona fide cell death 
regulator in the tail-spike cell, and is in fact a substitute for egl-1.  First, mutations 
in dre-1 block tail-spike cell death and these mutations can be rescued by cell 
autonomous expression of wild-type dre-1.  We would expect that, like the core 
cell death machinery, dre-1 would act in the cell that it was involved in killing.  
Second, the dre-1(ns39) mutation blocks tail-spike cell death in most animals, but 
in those animals in which the cell dies, the death appears normal, and a 
classically apoptotic corpse is evident by DIC microscopy.  Also, in those animals 
in which the tail-spike cell survives, it is morphologically indistinguishable from a 
surviving tail-spike cell seen in a ced-3, ced-4 or egl-1 mutant.  Thus, dre-1(ns39) 
does not cause a cell fate change such that the embryonic lineage is altered and 
the cell is never born or becomes a drastically altered cell.  Third, mutations in 
dre-1 synergize with mutations in core cell death components, suggesting that 
the dre-1 mutant background is sensitized with respect to tail-spike cell death.  
Furthermore, the genetic results show that dre-1 acts upstream of, or in parallel 
to ced-9 to regulate tail-spike cell death, and that pal-1 is downstream of dre-1 as 
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well.  These results do not address how dre-1 controls tail-spike cell death, but 
the domain structure of dre-1 hints at a role as an E3 ligase for the ubiquitin-
proteasome system. 
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Chapter 4:  DRE-1 acts in an SCF complex to regulate tail-spike 
cell death 
 
4.1 Background 
 The ubiquitin-proteasome system is the major control over protein turnover 
in eukaryotic cells, and as such plays a crucial role in all biologic processes.  The 
ability to precisely affect levels of individual proteins within the cellular 
environment allows fine tuning of cellular functions.  Among the most important 
processes to precisely control is cell death, as cell death regulators represent the 
seeds of a cells demise lurking within at all times.  Caspase activation in the 
wrong time and place can have disastrous implications for the organism, 
considering the feed forward mechanism built into the system.  In light of this, 
many levels of regulation have been built into the caspase activation process, 
including many examples of ubiquitin-proteasome related control.  The most 
important cell death-related ubiquitin ligases are the IAPs, which, in vertebrates 
and Drosophila, are vital regulators of caspases.  IAPs are RING domain-
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containing E3s, however, a different class of molecule from dre-1, which is an F 
box protein.  F box proteins are known to act as E3s through a multi-subunit 
complex, the SCF complex.  In these complexes, the E2-recruiting RING domain 
is supplied by an Rbx1/Roc1-like protein, which binds to a cullin scaffolding 
protein.  The cullin, in turn, binds to a SKP1-like protein which binds to the F box 
protein via the F box domain.  The F box protein supplies the specificity of the 
SCF E3 ligase, binding via its C-terminus to the substrate and bringing the target 
into position for ubiquitin to be conjugated to lysine residues in the polypeptide.  
To date, no SCF complexes have been reported as regulators of programmed 
cell death in C. elegans.  
 
 
4.2 Results 
Knockdown of dre-1, skr-1 or cul-1 prevent tail-spike cell death 
 dre-1 contains an F box near the N-terminus, known to bind to Skp1-like 
proteins which, along with cullin-like and rbx1-like proteins form an SCF complex 
to ubiquitinate target proteins.  Several lines of evidence suggested to us that 
dre-1 may act in an SCF complex regulate tail-spike cell death.  First, in all 
organisms harboring a dre-1-like gene, the F box is highly conserved.  For 
example, comparing C. elegans dre-1 to human FBXO11 with the ClustalW tool, 
16/41 residues are identical (39%), 12/41 residues are conserved based on 
charge and size (29%) and 7/41 are semi-conserved based on steric size and 
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shape (17%), bringing the total identical + conserved + semi-conserved to 35/41 
(85%).  Second, the strongest allele affecting tail-spike cell death (ns39) is a 
substitution in the F box changing a semi-conserved serine to a leucine (a 
residue of a different chemical class).  This serine is adjacent to a valine which is 
conserved in all organisms examined except Nematostella vectensis (sea 
anemone).  This valine is conserved in human, mouse, rat, Drosophila 
melanogaster, Xenopus laevis, Caenorhabditis brenneri, Caenorhabditis 
briggsae, Caenorhabditis japonica, Caenorhabditis remanei, Brugia malayi, 
zebrafish, Tetraodon nigroviridis (pufferfish), Aedes aegypti, Anopheles gambiae, 
Ixodes scapularis (black-legged tick), and Ciona intestinalis (sea squirt).  Third, 
Fielenbach et al. reported that dre-1 physically interacts with SKR-1 and SKR-2 
but not SKR-3, -4, -5, -7, -8, -9, -10, -12, -13, -14, -15, -17, -19, -20 or -21 in a 
yeast two-hybrid assay and that RNAi against skr-1, cul-1 and rbx-1/2 
recapitulated the dre-1 heterochronic phenotype. 
 While this is suggestive of dre-1 acting in an SCF complex to regulate tail-
spike cell death, we wanted to test the hypothesis directly by assessing the role 
of individual SCF genes in a reverse genetic manner.  To do so, we had to 
develop a method for screening a defined set of genes for a role in tail-spike cell 
death.  Using the RNAi feeding library available in the laboratory, we found that 
L4s and gravid young adults carrying an RNAi-sensitizing rrf-3(pk1426) mutation 
placed on a lawn of RNAi-expressing E. coli gave the strongest tail-spike cell 
death phenotype.  Feeding animals ced-4 RNAi in this assay resulted in 20% tail-
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spike cell survival illustrating that the penetrance of RNAi effects in this cell are 
incomplete (compare to the 100% survival in ced-4(n1162 animals)), but 
significant compared to empty-vector bacteria (0% survival) (Fig. 27).  In addition 
to ced-4, a second positive control for this assay was dre-1, which gave 10% 
survival. 
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Fig. 27.  Knockdown of ced-4 and dre-1 by feeding RNAi induces a partial 
tail-spike cell defect. 
L4 and gravid adults of the rrf-3(pk1426); nsIs25 genotype were placed on lawns 
of bacteria expressing empty vector, ced-4 RNAi and dre-1 RNAi.  L1 progeny 
were scored for tail-spike cell survival one and two days later (n>100 for each). 
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 With this method established, we tested the effect of knocking down skr-1, 
-2, -3, -5, -7, -8, -9, -11, -12, -13, -15, -17, -18, -19, -20, rbx-1, rbx-2, cul-1, -4, -5, 
and -6.  Of these genes, only cul-1 gave a significant phenotype: 9% tail-spike 
cell survival (Fig. 28).  This result is on par with the level of survival of animals 
grown on dre-1 RNAi, in which the tail-spike cell survives in 10% of animals.  
None of the skr genes gave a significant cell death phenotype, with skr-1 giving 
the largest effect, 2%. 
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Fig. 28.  Knockdown of cul-1 by feeding RNAi induces a partial tail-spike 
cell defect. 
L4 and gravid adults of the rrf-3(pk1426); nsIs25 genotype were placed on lawns 
of bacteria expressing the indicated RNAi.  L1 progeny were scored for tail-spike 
cell survival one and two days later (n>100 for each). 
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 Given that skr-1 and -2 were reported by Fielenbach et al. to interact with 
dre-1 in a yeast two-hybrid assay, and skr-1 RNAi had a very weak effect on tail-
spike cell death, we tested two genetic alleles of skr-1 for tail-spike cell 
phenotypes.  A deletion allele, ok1696, of skr-1 is viable as a homozygote with 
occasional dpy animals present on the plate.  skr-1(ok1696);nsIs25 animals had 
0% tail-spike cell survival, suggesting that either (1) skr-1 plays no role in tail-
spike cell death, (2) skr-2 or another gene is redundant and takes over in its 
absence, or (3) this allele is not a true null for skr-1.  Several lines of evidence 
suggest that the correct explanation is the third.  First, injection of skr-1 RNAi into 
hermaphrodite gonads produces embryonic lethality of most progeny due to 
hyperplasia during development (Yamanaka A et al., 2002; Nayak S et al., 2002), 
suggesting that the true phenotype of skr-1(null) is embryonic lethality and that 
the fully viable ok1696 allele is not a null.  Second, another deletion allele which 
we have not yet obtained, tm2391, is reported to be inviable as a homozygote 
and fails to complement the skr-1(sm151) point mutant (Killian DJ et al., 2008).  
Third, the skr-1(sm151) mutation, a weak semidominant allele that is viable, 
gives 4% tail-spike cell survival, compared to 0% for nsIs25 alone (Fig. 29).  This 
result shows that skr-1 (and possibly its close relative skr-2) is required for tail-
spike cell death. 
 A cul-1 allele (e1756) exists that has a sterile phenotype as a homozygote: 
cul-1 is maternally provided from a heterozygous mother to her homozygous 
progeny, who display a lon phenotype and whose progeny are embryonic lethal 
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due to lack of cul-1.  Because of this lethality phenotype, we were only able to 
score sterile animals, and of these, 0% had a surviving tail-spike cell (Fig. 29).  
With these limitations, we are unable to test genetically cul-1s role in tail-spike 
cell death, but given the RNAi phenotype, and that Fielenbach et al. also 
described a cul-1 RNAi phenotype for dre-1-related processes, we conclude that 
dre-1 acts in an SCF complex made up of dre-1, skr-1, cul-1 (and presumably 
rbx-1 and/or -2) to regulate tail-spike cell death. 
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Fig. 29.  The skr-1(sm151) weak loss-of-function allele weakly blocks tail-
spike cell death. 
Percent of animals with a surviving tail-spike cell in strains with the indicated 
genotypes (n>100 for each).  All strains contain the nsIs25 transgene to mark the 
tail-spike cell. 
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 Abida et al. reported that dre-1s human homolog, FBXO11, has the 
capability to neddylate proteins (Abida et al., 2007).  We tested whether RNAi 
against the C. elegans nedd (ned-8) affected tail-spike cell death.  0% of animals 
grown on ned-8 RNAi had surviving tail-spike cells, and we conclude that ned-8 
is not required for tail-spike cell death (Fig. 28). 
 
 
DRE-1 physically interacts with SKR-1 via the F box 
 These genetic data suggest a model in which DRE-1 binds to SKR-1 (and 
possibly SKR-2) which binds to CUL-1 and the remainder of the SCF complex to 
regulate tail-spike cell death.  As in other DRE-1-like proteins and their 
interactions with SKP-like proteins, the DRE-1-SKR-1 interaction should require 
an intact F box domain but not CASH domains.  To test this hypothesis, I 
performed immunoprecipitation experiments with myc- and HA-tagged forms of 
these proteins expressed in Drosophila Schneider S2 cells (Fig. 29).  
Immunoprecipitation with anti-HA-agarose beads successfully enriched for HA-
tagged DRE-1, DRE-1(ns39), DRE-1(dh99).  Western blot analysis for myc-
tagged SKR-1 showed that HA::DRE-1 and HA::DRE-1(dh99) but not HA::DRE-
1(ns39) or myc::SKR-1 alone immunoprecipitated myc::SKR-1.  That both the 
HA::DRE-1 and HA::DRE-1(dh99) proteins bound myc::SKR-1 but not HA::DRE-
1(ns39) are consistent with the F box being required for DRE-1-SKR-1 binding 
and gives biochemical logic to the genetic phenotypes of the dre-1(ns39) and 
dre-1(dh99) mutants.
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     1      2      3      4       5       6      7       8 
 
anti-myc immunoblot 
 
Lane 1:  myc::SKR-1  +  0, input 
Lane 2:  myc::SKR-1  +  HA::DRE-1, input 
Lane 3:  myc::SKR-1  +  HA::DRE-1(ns39), input 
Lane 4:  myc::SKR-1  +  HA::DRE-1(dh99), input 
Lane 5:  myc::SKR-1  +  0, IP anti-HA 
Lane 6:  myc::SKR-1  +  HA::DRE-1, IP anti-HA 
Lane 7:  myc::SKR-1  +  HA::DRE-1(ns39), IP anti-HA 
Lane 8:  myc::SKR-1  +  HA::DRE-1(dh99), IP anti-HA 
 
Fig. 30.  DRE-1 binds to SKR-1 and the ns39 F box mutation inhibits this 
interaction. 
myc::SKR-1 was expressed alone or in the presence of wild-type HA::DRE-1, 
HA::DRE-1 with the F box mutation (ns39), or HA::DRE-1 with the CASH domain 
mutation (dh99).  Immunoprecipitation was performed using anti-HA beads to 
enrich for HA::DRE-1 proteins, and immunoblotting was performed with anti-myc 
antibodies to detect myc::SKR-1.  The F box mutation affects SKR-1 binding to 
DRE-1, but the C-terminal CASH domain mutation does not. 
 
 
NB:  I plan to replace this blot with one that is better exposed in the coming 
weeks. 
 
 
SKR-1 
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4.3  Conclusions 
 Our results show that DRE-1, in concert with SKR-1, CUL-1, and, most 
likely, RBX-1/2 form an SCF complex to regulate tail-spike cell death.  Via either 
RNAi knockdown or genetic alleles we were able to observe tail-spike cell effects 
of loss of dre-1, skr-1 and cul-1.  In addition, our biochemical studies suggest that 
the interaction of DRE-1 with SKR-1 is mediated by the F box, and that the dre-
1(ns39) missense mutation affects this binding, while the dre-1(dh99) mutation 
does not.  These results are in line with earlier expression experiments which 
suggested that skr-1 and cul-1 are ubiquitous proteins, expressed during 
embryogenesis.  While these data show that the dre-1 SCF complex is an 
important regulator of tail-spike cell death, and establish this E3 ligase as the first 
to our knowledge to be involved with programmed cell death in C. elegans. 
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Chapter 5:  DRE-1/FBXO11 is mutated or deleted in human 
lymphomas and may interact with CED-9/BCL2 to induce its 
degradation 
 
5.1 Background 
 Evasion of apoptosis is a requirement of every cancer cell, as the 
accumulation of genotoxic stress, hypoxia, lack of growth factors and other 
insults should lead to the apoptotic removal of nascent tumor cells (Hanahan and 
Weinberg, 2000).  However, as evidenced by the high rate of p53 mutations in 
almost all cancers (greater than 50%), as well as the incidence of BCL2 
amplifications and translocations, these pro-death signals can be evaded through 
mutation.  Indeed, BCL2 was first described as a translocation partner with the 
immunoglobulin heavy chain locus in the t(14;18) translocation found in follicular 
lymphoma.  Further studies showed that BCL2 is dysregulated in many B cell 
lymphoma subtypes, including diffuse large B cell lymphoma, by translocation, 
genomic amplification and transcriptional upregulation (Lenz and Staudt, 2010).  
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Pro-apoptotic genes, such as p53, on the other hand, are frequently deleted or 
mutated to produce loss-of-function phenotypes, preventing apoptosis from 
proceeding.  Because of the conserved nature of dre-1 across metazoans, the 
central importance of ced-9 as the only known anti-apoptotic gene in C. elegans, 
the epistasis results suggesting that dre-1 acts upstream of or in parallel to ced-
9, and the frequency of BCL2 dysregulation in human lymphoma, we investigated 
whether FBXO11 acts as a tumor suppressor in human lymphoma and whether 
DRE-1/FBXO11 regulates CED-9/BCL2 turnover. 
 
5.2  Results 
DRE-1 and CED-9 interact with low affinity in Drosophila S2 cells 
 To test whether DRE-1 and CED-9 interact physically, we expressed 
HA::DRE-1 in the presence or absence of myc::CED-9 in Drosophila S2 cells and 
used magnetic beads to immunoprecipitate myc::CED-9 and anti-HA 
immunoblotting to detect HA::DRE-1 in the lysates (Fig. 31).  We observed a 
consistent increase in HA::DRE-1 detected in the lysates when myc::CED-9 was 
present compared with when myc::CED-9 was absent.  However, HA::DRE-1 
was also consistently weakly immunoprecipitated with anti-myc beads in the 
absence of myc::CED-9, and this non-specific interaction could not be eliminated 
by altering the wash buffer conditions as more stringent washes eliminated the 
specific interaction as well.  Therefore, we are able to detect an interaction, albeit 
a weak one, between DRE-1 and CED-9 in vitro. 
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        1      2       3      4 
 
 
 
Anti-HA immunoblot. 
Lane 1:  HA::DRE-1 + 0, input 
Lane 2:  HA::DRE-1 + 0, IP anti-myc 
Lane 3:  HA::DRE-1 + myc::CED-9, input 
Lane 4:  HA::DRE-1 + myc::CED-9, IP anti-myc 
 
Fig. 31.  DRE-1 and CED-9 interact with low affinity in Drosophila S2 cells. 
HA::DRE-1 was expressed alone (lanes 1 and 2) or together with myc::CED-9 
(lanes 3 and 4).  Immunoprecipitations were performed with anti-myc antibodies 
and immunoblotting with anti-HA antibodies to detect HA::DRE-1.  While some 
non-specific binding is present in lane 2, a specific interaction is apparent in lane 
4. 
 
 
 
 
 
 
 
 
 
 We also attempted to visualize CED-9 protein in the tail-spike cell, as one 
prediction from our model is that, in dre-1(ns39) mutants, CED-9 should 
accumulate due to a lack of dre-1 SCF activity.  We obtained an anti-CED-9 
antibody from Barbara Conradt, and used two fixation and staining protocols to 
immunostain ced-3(n2436) and dre-1(ns39);ced-3(n2436) animals.  We chose 
these strains as the ced-3 mutation would allow visualization of the tail-spike cell 
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in L1 animals in dre-1(wild-type) animals; otherwise, the cell would have died in 
embryogenesis.  Despite successful staining with another, unrelated antibody in 
these experiments (anti-AJM-1), we were unable to observe CED-9 staining in 
either strain.  This could be due to faulty staining with the anti-CED-9 antibody, to 
CED-9 levels being at a level below detection even in dre-1(ns39) animals, or to 
the dre-1(ns39) mutation not having an effect on CED-9 protein levels. 
 
 
FBXO11 is mutated or deleted in human lymphoma and these mutations 
cause reduced function 
dre-1 is one of the few F box proteins which is conserved across metazoans, with 
82% similarity to human FBXO11.  Given this remarkable similarity, we wondered 
whether it plays a role in apoptosis in other organisms, and specifically whether it 
could function as a tumor suppressor in human cancer.  In a serendipitous 
connection, I suggested this possibility to Dr. Louis Staudt at NCI, who noticed 
that certain lymphoma cell lines have deletions or mutations that affect the 
FBXO11 locus.  The Farage cell line contains a double deletion that removes 
FBXO11, the MedB1 line has a single deletion, and OCI-Ly1 contains a 
missense mutation as well as a nonsense mutation.  His group also identified 
mutations in FBXO11 when sequencing DNA derived from primary diffuse large 
B-cell lymphoma (DLBCL) tumor samples.  Four mutations were found in 
germinal center-like DLBCL (GCB-DLBCL), representing 5% of tumors 
sequenced and two mutations were found in activated B-cell-like DLBCL (ABC-
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DLBCL).  These mutations, with the mouse ENU-derived mutation (Jeff) and the 
C. elegans mutations, are a mixture of missense mutations and nonsense 
mutations, and are summarized below (Fig. 32). 
 
 
 
 
 
 
Fig. 32.  dre-1 and FBXO11 mutations from C. elegans mutants and patient 
samples. 
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 We wondered whether these mutations would affect dre-1 function in the 
tail-spike cell.  To address this question, we expressed mutant forms of the dre-1 
cDNA in the tail-spike cell using the aff-1 promoter and assessed their ability to 
rescue the dre-1(ns39) phenotype.  The Y560C mutation found in a lymphoma 
cell line susceptible to FBXO11 expression (see below), corresponds to the 
Y2218C mutation in C. elegans.  When modeled in the tail-spike cell, this mutant 
retained some rescue ability, but was less efficient at killing the tail-spike cell than 
the wild-type cDNA, resulting in 39, 41 and 45% tail-spike cell survival in three 
independent lines (Fig. 33).  The human nonsense mutation at position 256 was 
even less effective at rescuing tail-spike cell death, with the cell surviving 65% of 
the time.  These results show that the human mutations produce a hypomorphic 
protein, which is consistent with other loss-of-function mutations in tumor 
suppressor genes. 
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Fig. 33.  Mutated forms of DRE-1/FBXO11 found in lymphomas have 
reduced ability to rescue the dre-1(ns39) tail-spike cell death defect. 
DRE-1(2218) corresponds to the Y560C mutation in FBXO11; DRE-1(1960) 
corresponds to the 256Stop mutation in FBXO11.  All cDNAs were expressed 
using the aff-1 promoter.  Rescue of the dre-1(ns39) defect with the wild-type 
cDNA (aff-1p::DRE-1) is included for comparison.  n>100 for each. 
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Overexpression of FBXO11 in human lymphoma lines induces apoptosis 
 Given the role of dre-1 in apoptosis and the discovery of possible loss-of-
function mutations in human lymphomas, it is possible that FBXO11 is a pro-
apoptotic gene in human cells.  If so, then its expression might induce death, a 
possibility that Lixin Rui, a post-doctoral fellow in Dr. Staudts lab, investigated 
(all experiments described below involving human cells were performed by Dr. 
Rui).  Transduction of a panel of lymphoma cell lines with a retrovirus expressing 
FBXO11 and GFP allowed the toxicity of FBXO11 to be evaluated via flow 
cytometry.  While 11/18 lines showed no effect on viability over 8 days post-
transduction, 7/18 exhibited a clear cell death phenotype (Fig. 34).  Importantly, 
the three lines with deletions or mutations in FBXO11 – MedB1, Farage and OCI-
Ly1 – showed a marked decrease in viability after FBXO11 expression, 
suggesting that loss of FBXO11 made these lines especially vulnerable to 
reintroduction of FBXO11. 
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Fig. 34.  Induction of FBXO11 expression kills certain lymphoma cell lines. 
Various DLBCL cell lines and two Hodgkin lymphoma cell lines, as indicated, 
were transduced with FBXO11 retrovirus. FBXO11-expressing cells were 
monitored by flow cytometry for a co-expressed GFP marker. The percentage of 
live GFP-positive cells for each time point was normalized to day 0.  Lixin Rui and 
Lou Staudt, unpublished data. 
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 This cell death phenotype was accompanied by hallmarks of apoptosis.  
Farage and MedB1, two of the lines most susceptible to FBXO11-induced death, 
showed an increase in cleaved PARP as well as active caspase-3 as assayed by 
flow cytometry (Fig. 35).  VP16 expression was used as a positive control for 
induction of apoptosis. 
 FBXO11 induction did not affect the cell cycle in either cell line (Fig. 36). 
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Fig. 35.  FBXO11 expression induces apoptosis in lymphoma cell lines. 
Analysis of apoptosis with active caspase-3 and cleaved PARP in Farage and 
MedB1 cells expressing FBXO11 for the indicated times.  Positive control cells 
were treated with VP16 as indicated times and concentrations. Lixin Rui and Lou 
Staudt, unpublished data. 
 
 
 
 
 
Fig. 36.  FBXO11 expression does not affect the cell cycle. 
Flow cytometric analysis of the cell cycle in Farage and MedB1 cells induced for 
the expression of the FBXO11 for the indicated days. Empty vector served as a 
control.  Lixin Rui and Lou Staudt, unpublished data. 
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FBXO11 kills lymphoma cells via degradation of BCL2 
 Because of the apparent connection between dre-1 and ced-9 in C. 
elegans, Dr. Rui tested whether induction of FBXO11 expression in Farage cells 
affected BCL2 levels.  Remarkably, BCL2 levels decreased over the course of 4 
days of FBXO11 expression, while no such change occurred in empty vector 
transduced cells (Fig. 37).  This reduction in BCL2 protein level was evident both 
via immunoblot and flow cytometry. 
 
 
 
 
Fig. 37.  BCL2 protein levels fall after FBXO11 expression. 
(A) Immunobloting analysis of BCL2 levels after FBXO11 induction in Farage 
cells. The cells were transduced with FBXO11 or empty vector virus with 
puromycin selection marker and then induced for the expression of the FBXO11 
for the indicated days.  
(B) Flow cytometric analysis of the levels of BCL2 in the cells treated as in A. 
Lixin Rui and Lou Staudt, unpublished data. 
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 Cell killing was significantly reduced when using mutant forms of FBXO11 
derived from patient samples, the mouse mutant, and C. elegans mutants (Fig. 
38).  Furthermore, the potency of killing was well-correlated with the level of 
reduction of BCL2 protein detected by flow cytometry. 
 
 
 
 
 
 
Fig. 38.  The ability of FBXO11 to kill lymphoma cells and affect BCL2 
levels is diminished in mutant forms of the protein. 
(A) Farage cells were transduced with various mutant FBXO11 viruses and then 
expression was induced for 6 days. Shown is flow cytometric analysis of the 
levels of BCL2 protein. 
(B) Farage cells were transduced with various FBXO11 retrovirus as indicated. 
FBXO11-expressing cells were monitored by flow cytometry for a co-expressed 
GFP marker. The percentage of live GFP-positive cells for each time point was 
normalized to day 0.   
FBXO11 mutations: Y560C from OCI-Ly1 GCB cell line, T241A and stop256 (N-
terminal 256 aa) from GCB patient samples.  S244L from mouse ENU 
mutagenesis model.  C99L, G420S and stop730 from C. elegans mutations.  C-
terminus (deletion of F-BOX domain) as a control.  Lixin Rui and Lou Staudt, 
unpublished data. 
 
A B 
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 To test whether overexpression of BCL2 could rescue the toxicity of 
FBXO11, HA-BCL2 was transduced into Farage cells and single cell clones 
expressing GFP and BCL2, or GFP and empty vector were selected.  Those 
clones that expressed low levels of BCL2 (#9 and 10, as well as empty vector), 
but not those that expressed higher levels of BCL2 (#13, 15, 3, 11) were killed by 
FBXO11 induction (Fig. 39).  Thus, a threshold level of BCL2 expression was 
required to rescue FBXO11 toxicity in Farage cells. 
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Fig. 39. Overexpression of BCL2 rescues the toxicity of FBXO11 to Farage 
cells.   
Top panel: HA-BCL2 was transduced in Farage cells and single cell clones were 
obtained after hygromycin selection. These single cell clones were individually 
infected with FBXO11 retrovirus or empty vector with a GFP marker. Live 
FBXO11-expressing, GFP+ cells were monitored by flow cytometry over time 
following FBXO11 induction. Data were normalized today 0.  
Bottom panel: Flow cytometric analysis of the levels of BCL2 protein in panel A 
samples after 6 days induction of FBXO11 compared to day 0.  Lixin Rui and Lou 
Staudt, unpublished data. 
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 The Farage line was selected for FBXO11 induction experiments because 
it completely lacks endogenous FBXO11 expression and is highly susceptible to 
killing upon FBXO11 reintroduction.  However, to test whether FBXO11 and 
BCL2 interact physically, Dr. Rui used the Riva and OCI-Ly1 lines, which 
endogenously express FBXO11 and BCL2 but are also killed upon FBXO11 
overexpression.  Immunoprecipitation of lysates from Riva and OCI-Ly1 with an 
FBXO11 antibody but not a control antibody led to detection of BCL2 via 
immunoblotting (Fig. 40).  Immunoprecipitation with the FBXO11 antibody from 
Farage serves as a negative control, since it expresses no FBXO11 but a large 
amount of BCL2. 
 
 
 
 
 
Fig. 40.  FBXO11 and BCL2 interact in Riva and OCI-Ly1 cell lines. 
Immunoprecipitation with FBXO11 antibody but not a control antibody reveals an 
interaction between FBXO11 and BCL2.  FBXO11 band is indicated by arrow.  
Lixin Rui and Lou Staudt, unpublished data. 
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 The proteasome inhibitor PS-341 was used to test whether reduction of 
proteasome function would affect BCL2 immunoprecipitation with FBXO11.  In 
both Riva and OCI-Ly1, there was an increase in BCL2 immunoprecipitated in 
the presence of PS-341, compared to no drug (Fig. 41, top panel).  In the Riva 
cell line, this increase in BCL2 was evident over the 3 hour time course, as was a 
band corresponding to BCL2 in the anti-ubiquitin blot (Fig. 41, middle panel).  
The reciprocal experiment, in which BCL2 was immunoprecipitated in the 
presence of PS-341 and the lysate probed for FBXO11 showed a similar modest 
increase in FBXO11 over the 3 hour time course (Fig. 41, bottom panel).  These 
results suggest that FBXO11 and BCL2 interact in these cell lines and their 
interaction is enhanced in the presence of the proteasome inhibitor PS-341. 
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Fig. 41.  Proteasome inhibition enhances BCL2 immunoprecipitation by 
FBXO11. 
Cell lines were treated with PS-341 proteasome inhibitor for the indicated times 
and immunoprecipitated with antibodies against either FBXO11 or BCL2 and 
immunoblotted for the other.  Lixin Rui and Lou Staudt, unpublished data. 
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5.3  Conclusions 
 Our results, in collaboration with Lou Staudt and Lixin Rui, suggest that 
FBXO11 is mutated in human lymphoma, and these mutations are loss-of-
function mutations, both in the context of human cells and the tail-spike cell.  
Also, reintroduction of FBXO11 into human lymphoma cell lines that have lost the 
gene leads to their apoptotic death, and BCL2 overexpression can rescue this 
cell killing.  FBXO11 interacts with BCL2 in lymphoma cells and leads to its 
degradation.  Finally, we present evidence suggesting that DRE-1 and CED-9 
physically interact in vitro, though we are unable to detect CED-9 protein in the 
tail-spike cell of dre-1(ns39) mutants by immunofluorescence.   
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Chapter 6:  Characterization of global ced-3 transcription and a 
mutant that affects ced-3 transcription in the  tail-spike cell 
 
6.1  Background 
 Tail-spike cell death is unique in several ways, including the fact that it 
occurs a long time after the cell is born.  Maurer et al. showed that a ced-
3pro::gfp transcriptional reporter is activated just before the cell dies, suggesting 
that ced-3 transcription is the trigger for the cell to die (Maurer et al., 2007).  
Furthermore, deletion of three small, conserved regions within the promoter 
abolished ced-3pro::gfp expression, showing that transcription factors must bind 
to the promoter to activate transcription.  A forward genetic screen for mutants in 
which the ced-3pro::gfp construct fails to be activated identified three 
independent mutants, ns114, ns115 and ns90.  ns114 and ns115 mapped to the 
pal-1 gene, a homeodomain transcription factor important in many cell fate 
decisions during development.  Electrophoretic mobility shift assays showed that 
PAL-1 binds to the ced-3 promoter to control tail-spike cell death, and the pal-
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1(ns114) and ns115 loss-of-function alleles block tail-spike cell death.  These 
results established the importance of ced-3 transcription in control of tail-spike 
cell death, but little was known about ced-3 transcription in other cells.  In 
addition, the ns90 mutation, which completely blocks ced-3 transcription in the 
tail-spike cell, remained uncloned.  We set out to address these two issues. 
 
6.2  Results 
ced-3 is transcribed in most cells during development, including many that 
do not undergo programmed cell death 
 To create a transcriptional reporter that would include all relevant promoter 
sequences, we used the pJ40 plasmid, which has been shown to rescue the cell 
death defect of ced-3 mutants (Yuan et al., 1993).  Into this plasmid, which 
contains 7.6 kb of ced-3 genomic DNA, we inserted the GFP sequence, followed 
by a stop codon.  Thus, this construct encodes a protein containing the first 69 
amino acids of CED-3 fused to GFP, followed by a long 3'UTR that includes the 
remainder of the ced-3 gene and its own 3'UTR.  Because such complicated 
mRNAs may be degraded by nonsense-mediated decay, we injected this 
construct into smg-1(r861) animals, which have been reported to allow 
expression of such transgenes (Wilkinson et al., 1994). 
 This reporter turned on ~100-150 minutes post-fertilization and expressed 
in most cells until the end of the comma stage of embryogenesis (Fig. 42).  At 
this time, GFP was expressed in fewer and fewer cells, until hatching when GFP 
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was only reliably expressed in the tail-spike cell and occasionally in cells in the 
head (Fig. 42c).  In addition, ced-3 was also expressed in the male tail in L4 
animals (Fig. 42d). 
 Having established that ced-3 is transcribed in the tail-spike cell just 
before its death, we wondered whether a similar mechanism acted in other dying 
cells.  To address this, we studied this reporter in smg-1(r861); ced-3(n717) 
animals, and found that there was no change in the expression pattern.  If ced-3 
transcription is upregulated in all doomed cells just before their deaths, we would 
expect to see many cells in this strain that turned on the reporter just before their 
scheduled death but continued to express GFP after they survived 
inappropriately.  Instead, we saw no evidence of these surviving, GFP-
expressing cells, including in larvae in which cells die post-embryonically.  
Instead, we saw no significant GFP expression in larvae outside the tail-spike cell 
(Fig. 42e).  We conclude that ced-3 is transcribed in 100-150 minute embryos, 
and this mRNA or protein is inherited during development, when it can become 
activated in cells destined to die. 
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Fig. 42.  ced-3 is transcribed in many cells during developmental periods of 
cell death. 
Top and bottom panels for each image are DIC+fluorescence and fluorescence-
alone images, respectively.  (A) Image of a smg-1(r861) embryo expressing a 
transgene consisting of the full rescuing (7.6 kb) ced-3 genomic locus, into which 
GFP with a nuclear localization signal near the start codon was inserted.  (B) 
Same as A.  Notice cell corpse (circled) weakly expressing GFP.  (C) A smg-
1(r861) larva containing the same transgene as in A.  Notice the absence of GFP 
expression.  The observed fluorescence is caused by autofluorescence from gut 
granules.  (D) A smg-1(r861) L4 male larva containing the same transgene as in 
A.  Notice the bright expression in several cells in the tail.  None of these cells is 
fated to die.  (E) A smg-1(r861); ced-3(n717) larva containing the same 
transgene as in A.  Notice the GFP expression in the tail-spike cell (arrows). 
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ns90 blocks ced-3 transcription and apoptosis in the tail-spike cell 
 The ns90 mutation was isolated from a screen for regulators of ced-3 
transcription in the tail-spike cell.  ced-3(n717); ced-3pro::gfp animals, in which 
the tail-spike cell survives inappropriately in 100% of animals and expresses 
GFP, were mutagenized and F2 progeny in which ced-3pro::gfp was no longer 
present were sought.  Three mutants were isolated from this screen, ns114, 
ns115 and ns90.  ns114 and ns115 were shown to be partial loss-of-function 
alleles of pal-1, in which the block in ced-3 expression in the tail-spike cell was 
incomplete.  ns90, on the other hand, produces a complete block in tail-spike cell 
ced-3 transcription, such that the nsIs25 transgene is off in 100% of animals.  In 
addition, ns90 is a semi-dominant mutant, as 96% of heterozygotes also lack 
ced-3 transcription in the tail-spike cell. 
 Because of the complete block in ced-3pro::gfp expression in ns90 
mutants, we are unable to assess whether the mutation has an effect on tail-
spike cell death or if it is instead never born.  To circumvent this issue, we 
crossed the ns90 mutation to the ced-5(n1812) background, in which apoptotic 
corpses persist inappropriately, allowing us to determine whether the cell has 
died.  In ns90; ced-5(n1812) animals, a corpse is present in 41% of animals and 
absent in 59% (Fig. 43).  These data suggest that the tail-spike cell is born and 
dies in less than half of animals, and in the remainder it is born and survives 
inappropriately, even though we are unable to visualize it with the ced-3pro::gfp 
reporter. 
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Fig. 43.  The ns90 mutation blocks tail-spike cell death in addition to ced-3 
transcription in the tail-spike cell. 
Left:  The tail of a ced-5(n1812) engulfment defective L1 larva in which the round, 
button-like tail-spike cell corpse is evident in DIC and fluorescence. 
Right: The tail of an ns90; ced-5(n1812) larva in which no corpse is evident.  59% 
of animals of this genotype fail to display a corpse, suggesting that the ns90 
blocks tail-spike cell death in 59% of animals.  All animals contain the nsIs25 
transgene as a marker for ced-3 transcription in the tail-spike cell.  n=30. 
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 Because the ns90 mutation appears to not only affect ced-3 transcription 
but also tail-spike cell death, we set out to map this mutant via standard SNP-
mapping techniques.  However, because of the allele's dominance, we were 
forced to map the mutation based on the absence of the phenotype, i.e., picking 
recombinants in which the phenotype and mutation were lost.  We were able to 
map the mutation to a 0.25 MU interval on Chromosome II between T05C12.9 
(0.75 MU) and nfi-1 (0.5 MU).  We sequenced several genes in this interval, 
including lir-1, lir-2 and lin-26, and identified a mutation in lin-26.  This mutation, a 
G to A change in the first zinc finger of the protein, is predicted to substitute an 
isoleucine for a methionine.  Because of the difficulty of rescuing dominant 
mutations, we attempted to induce the ns90 phenotype in wild-type animals by 
expressing the mutated form of lin-26 in the tail-spike cell.  This strategy proved 
unsuccessful, as 100% of ced-3; nsIs25 animals carrying this transgene retained 
ced-3pro::gfp expression (n=30).  Thus, we are unable to determine whether the 
mutation in lin-26 is responsible for the ns90 phenotype. 
 
6.3  Conclusions 
We have shown that the ced-3 caspase is expressed in most cells during 
embryogenesis, including cells that do not undergo programmed cell death.  This 
result is consistent with previous work showing that cells that do not undergo 
programmed cell death retain the pro-death activity of ced-3, although this killing 
activity is kept in check (Shaham and Horvitz, 1996b).  Thus, it appears that ced-
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3 is transcribed relatively early in embryogenesis, and either the transcript or 
protein is inherited during cell divisions until it is activated in cells fated for 
programmed cell death.   
 In addition, we showed that the ns90 mutation, which was known to block 
ced-3 transcription in the tail-spike cell, also prevents tail-spike cell death.  We 
were unable to conclusively identify the gene relevant for the ns90 phenotype, 
although we did identify a mutation in lin-26, a zinc-finger transcription factor 
(Labouesse et al., 1994).  The mutation present in the ns90 strain is a 
substitution in the first zinc-finger domain, which could disrupt binding of LIN-26 
to the ced-3 promoter.  Indeed, while PAL-1 binds to the ced-3 promoter in two 
defined domains, the transcription factor(s) that bind to the third domain shown 
by Maurer et al. to be important for ced-3 transcription in the tail-spike cell remain 
unknown (Maurer et al., 2007).  It is possible that LIN-26 is the relevant 
transcription factor, and the mutation we identified disrupts the ability to bind to 
this site.  It is unclear why such a mutation would be dominant and so highly 
penetrant, although if LIN-26 acts in a dimer it could bind to and inactivate the 
wild-type form of the protein.  Regardless, further work is required to elucidate the 
molecular basis of the ns90 mutation. 
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Chapter 7:  Discussion and Future Directions 
 
 Programmed cell death is a process crucial to the development of 
metazoans, and the genes underpinning this process are functionally important 
for development and disease, as well as fundamental to how life works.  We have 
used the C. elegans tail-spike cell as a model for uncovering genes relevant to 
cell death, and these studies have revealed that a conserved F box protein, dre-
1, is required for tail-spike cell death. 
 dre-1 acts within an SCF complex to regulate death, and represents a new 
mode of cell death control that bypasses egl-1 to control caspase activation.  dre-
1 requires ced-9 for the majority of its function, suggesting that dre-1 acts 
upstream of and/or in parallel to ced-9.  Given that SCF complexes are known to 
induce ubiquitination and degradation of target proteins, and with our 
collaborators' results showing that FBXO11 and BCL2 interact physically, we 
favor a model in which the DRE-1 SCF complex inhibits CED-9 function directly, 
via ubiquitin-mediated proteolysis (Fig. 44).  The ced-9 epistasis results suggest 
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this model, but they also suggest that dre-1 may function via another, ced-9-
independent pathway.  This is because in the absence of ced-9 function (i.e., the 
ced-9(n2812) null mutation), the tail-spike cell still survives in 20% of animals.  
The only caveat to this result is that this strain contains three mutations, dre-
1(ns39), ced-9(n2812) and ced-3(n2427), as well as the tail-spike cell integrated 
marker, making it possible that this highly unnatural state produces other effects 
that prevent tail-spike cell death (for example, ced-4 expression could be 
affected).  This result leads us to place dre-1 upstream of ced-9, but also in 
parallel to it. 
 Our model also assumes that rbx-1 and/or -2 are part of the SCF complex 
that regulates tail-spike cell death.  While we did not observe a tail-spike cell 
death phenotype for these genes, they are likely part of this complex, fulfilling the 
crucial E2 recruitment role.  The lack of a discernable tail-spike cell phenotype in 
rbx-1 or -2 RNAi may be due to the difficulty of performing RNAi in the tail-spike 
cell: even in the rrf-3 RNAi-sensitized background, knockdown of ced-4, which 
we would expect to give 100% survival based on the ced-4(n1162) allele, gives 
only 20% survival, illustrating that RNAi by the feeding method has a very weak 
effect in the tail-spike cell.  Thus it is possible that the RNAi clones directed 
against rbx-1 and rbx-2 are unable to sufficiently knockdown the genes' function 
in order for us to observe an effect in the already weak tail-spike cell RNAi assay.  
Furthermore, feeding RNAi does not allow us to knockdown both genes 
simultaneously, so it is likely that knockdown of one gene results in redundant 
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compensation by the other.  Thus, we are confident that DRE-1 acts in an SCF 
complex with SKR-1, CUL-1 and RBX-1/2. 
 Our model also suggests that DRE-1 acts directly on CED-9 to regulate 
cell death.  As has been the case with many other E3 ligases, defining the 
target(s) of dre-1 has been very difficult.  We attempted to demonstrate an 
interaction between DRE-1 and CED-9 and found that they interact with weak 
affinity in vitro.  That this interaction is difficult to detect may be due to the fact 
that we lack a C. elegans system in which DRE-1 and CED-9 are endogenously 
co-expressed, and instead we must ectopically express these proteins in 
Drosophila cells.  If modifications are necessary to regulate this interaction, as is 
often the case in F box protein/substrate interactions, they may not be occur in 
this context.  Also, because we lack specific antibodies appropriate for 
immunoprecipitation of DRE-1 and CED-9, we must use tagged forms of these 
proteins, which may affect their ability to interact.  However, our results give 
evidence for a weak interaction of CED-9 and DRE-1. 
 118 
 
 
 
 
 
  dre-1    ? 
 
 egl-1  ced-9   ced-4              ced-3     Apoptosis 
       (BH3-only)       (BCL2)            (Apaf1)          (caspase) 
 
 
Fig. 44.  A model for dre-1s role in tail-spike cell death. 
Our results suggest that dre-1, in concert with its SCF complex partners (not 
shown), acts upstream of, or in parallel to ced-9, and may also act independently 
of ced-9 to regulate tail-spike cell death. 
 
 
 
 
 
 What future experiments could allow us to identify the target(s) of DRE-1 
in an unbiased manner?  First, a genetic screen for dominant mutations that 
prevent tail-spike cell death could be informative.  Indeed, we attempted such a 
screen, and isolated one mutant, ns312, but were unable to clone it, as it 
appeared to map to two separate loci and was not strongly dominant.  However, 
a more exhaustive screen of this variety could isolate a dominant-negative form 
of an anti-apoptotic regulator, as ced-9(n1950) was isolated from screens for 
inappropriate cell survival.  A dominant mutant might represent a mutation that 
prevents dre-1's target from interacting with the SCF complex and thus from 
being ubiquitinated.  In that case, the anti-apoptotic activity of the target protein 
would persist and prevent the tail-spike cell from dying.  The major caveat to this 
screen is that such a mutant may not exist: there may not be a mutation that 
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prevents binding of this anti-apoptotic protein to the dre-1 SCF complex while 
also leaving its anti-apoptotic function intact.  Indeed, our failed attempts at 
isolating such a mutant provide support to this idea, although our screen was not 
exhaustive and further attempts could prove fruitful here. 
 A related experiment could address whether CED-9 is the relevant target 
of DRE-1 in tail-spike cell death.  Wild-type and un-ubiquitinatable ced-9 could be 
expressed in the tail-spike cell, and assayed for their ability to prevent tail-spike 
cell death.  If ubiquitin-mediated destruction or inhibition is necessary for tail-
spike cell death, then the un-ubiquitinatable form would be expected to prevent 
death at a higher rate than the wild-type form.  This experiment is difficult, 
however, for two reasons.  First, there are 13 lysines in CED-9, and it is 
impossible to know, a priore, which are relevant.  It is intriguing, however, that 
CED-9, BCL2 and many of their homologues share a terminal lysine residue.  
Second, we know that there is at least one form of CED-9 that dominantly 
prevents cell death, n1950, through its egl-1-related interaction.  While this 
interaction plays a minor role in the tail-spike cell, it might complicate the 
interpretation of the results.  Third and most importantly, the level of expression 
of wild-type and mutant forms of CED-9 are crucial determinants in this 
experiment.  C. elegans transgenics are known to vary significantly in the copy 
numbers of the introduced genes.  If either the wild-type or mutant forms of CED-
9 were expressed at a very high level, the amount of tail-spike cell death in the 
strain could be affected, as in either case, high expression of an anti-apoptotic 
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protein should prevent death.  Excess tail-spike cell survival due to high 
expression of CED-9 would have to be distinguished from physiologic expression 
of a mutant form that accumulates due to lack of proteasome-induced turnover. 
 A second avenue toward identifying the target of DRE-1 would be to clone 
more mutants from the screen that yielded the dre-1(ns39) mutant.  Because 
many F box protein-substrate interactions require phosphorylation or other 
modification for efficient binding, it is likely that there are other genes involved in 
dre-1's pro-apoptotic function in the tail-spike cell.  Indeed, another mutant, ns40, 
fails to complement dre-1 and does not have a global cell death defect, 
suggesting that this may be an interesting mutant.  Also, the screen that isolated 
ns39 and ns40 is not saturated, so more interesting mutants may be available 
after further screening. 
 Third, DRE-1 binding partners could be isolated with a biochemical 
screen.  For example, a tagged form of DRE-1 could be used to rescue the tail-
spike cell death defect and then an antibody against the tag could be used to 
isolate DRE-1 and proteins bound to it.  Knowing that the tagged form rescued 
the death defect would assure that full dre-1 activity was present in the 
ectopically-expressed strain.  The protein isolation would ideally be done in 
embryos, when dre-1 acts in the tail-spike cell; otherwise, dre-1 targets relevant 
to heterochronic or early development phenotypes might be isolated instead.  Not 
only is this a difficult experiment because of the inherent difficulty in performing a 
biochemical screen, but also because the tail-spike cell is one of ~1000 cells in 
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the animal, and thus the relevant interaction might be below the level of 
detection. 
 Finally, to investigate further whether CED-9 is the target of DRE-1, 
biochemical isolation of CED-9 protein from C. elegans embryos followed by 
biochemical analysis could be done.  If CED-9 is polyubiquitinated, 
phosphorylated, or otherwise modified, these modifications might be discernible 
by mass spectrometry.  While this may be less successful in whole C. elegans 
embryos, as the tail-spike cell is one of many cells, it might be more successful in 
human lymphoma cells susceptible to FBXO11-induced killing.  Identification of 
the residues relevant for ubiquitination or other modification would allow those 
amino acids to be specifically targeted for mutagenesis in further studies. 
 While we have focused on the cell death-related target(s) of DRE-1, it 
would also be interesting to understand what are the other DRE-1 targets that 
govern other developmental processes.  For example, dre-1(null) mutants die 
during embryogenesis due to severe patterning defects that are unrelated to cell 
death.  In addition, Fielenbach et al. described a role for dre-1 in heterochronic 
phenotypes in larvae (Fielenbach et al., 2007).  While these functions are clearly 
separable from dre-1's cell death function (that the ns39 mutant is viable but has 
a strong tail-spike cell death defect demonstrates this), they may be in some way 
shed light on the apoptotic role.  A relatively simple screen would be for 
suppressors of the lethality of a dre-1(null) mutation. 
 We showed that most aff-1 mutant animals have a forked tail as L1s, and 
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this defect is likely to be due to tail-spike cell non-fusion because fusion of hyp10, 
the cell that makes up the tail tip, is governed by eff-1.  We have not, however, 
formally proved this, as it is possible that the aff-1 mutation affects tail-tip 
morphogenesis via another cell, despite the fact that aff-1 is expressed in the tail-
spike cell but not hyp10.  To formally prove that tail-spike cell fusion must occur 
for proper tail-tip morphogenesis, we would have to rescue the aff-1 mutation in 
the tail-spike cell only.  However, no promoter is known that expresses 
specifically in the tail-spike cell at an early stage in development. 
 Our results also suggest that the tail-spike cell process is vital for hyp10 
morphogenesis, and when the cell does not fuse, two processes are produced 
which direct formation of a forked tail, instead of a normal one.  To more directly 
address this hypothesis, we could ablate either the developing tail-spike cell soon 
after its birth, or the process as it has just begun to form.  We would expect that 
in either case, hyp10 would be unable to properly form a tail-tip, a defect that 
might manifest itself as a blunted tail.  The difficulty with this experiment is that 
ablations would have to be performed in 3-fold embryos in which the animals are 
able to roll within the eggshell.  Thus, it would be difficult to ablate such a small 
cell, or, better, its even smaller process, in a moving target. 
 
 When we recognized that dre-1 is a conserved apoptotic regulator, we 
wondered whether its cell death role was conserved, and whether it might act as 
a tumor suppressor in human cancer.  Our collaborators at the National Cancer 
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Institute, Lou Staudt and Lixin Rui, identified human lymphoma cell lines and 
patient samples with deletions and mutations in the FBXO11 gene consistent 
with the idea that FBXO11 controls apoptosis in human lymphoma (that tail-spike 
cell death is governed by two suppressors of human cancer, pal-1/Cdx2 and dre-
1/FBXO11, is truly remarkable).  They went on to show that FBXO11 expression 
in the cells that had deleted it caused their death, suggesting that, because of the 
genetic wiring of these particular cell lines, FBXO11 is especially toxic.  In 
addition, they were able to show that FBXO11 and BCL2 interact in the cells in 
which both are endogenously expressed, and that BCL2 levels fall upon FBXO11 
expression. 
 An ENU-induced mutant in FBXO11 has been described, the so-called 
Jeff mouse, which is likely a hypomorphic mutation that leads to perinatal lethality 
in homozygotes.  Because these mice do not survive beyond a few hours after 
birth, we cannot test whether they are cancer-prone.  However, as heterozygotes 
these animals are viable and show only an inner ear defect.  To address whether 
FBXO11 plays a role in tumor suppression in mice, these heterozygotes could be 
monitored for spontaneous tumor development, although the Jf/+ reduction of 
function may not be a strong enough FBXO11 defect to induce tumor formation.  
In that case, Jf/+ heterozygotes could be crossed to one of many tumor-prone 
mouse models, such as the Eμ-myc model.  In these mice, the myc oncogene is 
driven by the immunoglobulin heavy chain enhancer, and nearly all mice 
containing this transgene develop lymphomas at a young age.  If FBXO11 is 
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involved in B cell death, Jf/+ Eμ-myc mice might develop tumors at an earlier 
age, or their tumors might be more virulent 
 Another interesting experiment would be to conditionally inactivate 
FBXO11 in B cells, replacing the coding sequence in B cells with GFP via the 
Cre-lox or other related system.  This would allow monitoring of B cell 
development in the absence of FBXO11, which might elucidate the step at which 
the gene is acting.  Simultaneously, it would give information about when during 
B cell development FBXO11 is normally expressed.  Because B cells may 
undergo apoptosis at many steps during their maturation, from early stages when 
they must successfully rearrange their immunoglobulin loci to form a competent B 
cell receptor, to later stages when they may be deleted based on the affinity of 
their receptor for self- and non-self-antigen.  We would predict, based on the 
mutations found in DLBCL, that FBXO11 is more likely to act in later B cell 
development, as these tumors express gene signatures seen in later stage B 
cells.  A detailed examination of FBXO11 expression in normal B cells with an 
anti-FBXO11 antibody would further our understanding of its role in B cell 
development. 
 A related experiment that would help to understand the role of FBXO11 in 
vertebrate systems would be the creation of a GFP knock-in mouse to replace 
the FBXO11 locus in all cells.  This would allow the FBXO11 expression pattern 
to be studied in detail during development, along with the null phenotype.  We do 
not know how far these mice would develop, but if they survived long enough in 
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embryogenesis, we would learn in which tissues FBXO11 is expressed with more 
accuracy than has been reported via immunostaining.   
 The Jf/Jf mouse has been reported to possess craniofacial abnormalities 
and cleft palate, and shows reduced staining of cleaved caspase-3 in the 
developing palate (Tateossian et al., 2009).  Intriguingly, Apaf-1 mutants were 
also reported with facial deformities and cleft palate (Cecconi et al., 1998).  While 
there are many mouse mutants with these phenotypes, it is tempting to think that 
both the FBXO11 and Apaf-1 defects are cell death-related defects.  To address 
this question, it would be informative to stain the developing palates of Jf/Jf mice 
for Apaf-1 and BCL2, as well as Apaf-1(null) mice for FBXO11 expression; 
perhaps the expression of one depends on the presence of the other.  Also, 
developing palates of wild-type mice could be stained for these proteins, as they 
may be expressed in a subset of cells that must undergo programmed cell death 
for a normal palate to be formed. 
 Finally, because of the connection between FBXO11 and BCL2, and 
because BCL2 is expressed in tissues outside B cells and has been implicated in 
many other cancers, sequencing of the FBXO11 locus in other tumor types could 
be informative.  While Rui and Staudt found FBXO11 mutation in 5% of germinal 
center-like DLBCLs, it is possible that the gene is mutated in other tumor types at 
a higher rate.  In addition, Tateossian et al. reported that FBXO11 is expressed in 
many tissues of the mouse, including lung, brain, bone marrow and kidney.  If the 
human FBXO11 expression pattern is similar, then FBXO11 may have a role in 
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the development of these tissues and may also have tumor suppressive activity 
in these tissues.  With the ongoing Cancer Genome Atlas and other deep 
sequencing projects in progress, we may learn of FBXO11 mutations in other 
cancers. 
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Chapter 8:  Materials and Methods 
 
Strains 
All strains were maintained at 20oC on NGM agar with OP50 bacteria.  The wild-
type strain was N2 Bristol.  The following strains were used: 
LGI:  mir-71(n4115), mir-2(n4108), lin-28(n719), skr-1(sm151, ok1696) 
LGII:  aff-1(tm2214), eff-1(hy40), ns90, lin-29(n333), lin-4(e912), rrf-3(pk1426)  
LGIII:  ced-4(n1162, n ), ced-9(n2812, n1950), pal-1(ns114, ns115), cul-1(e1756) 
LGIV:  ced-3(n717, n2427, n2436, ns38), ced-5(n1812) 
LGV:  dre-1(ns39, dh99, dh279, gk857), egl-1(n1084n3082), lin-46(ma164) 
LGX:  nsIs25 
 
Plasmid construction 
For the dre-1 transcriptional reporter, 4 kb of genomic DNA upstream of dre-1 
exon 2 was amplified by PCR with SalI and BamHI sites incorporated into the 
primers and the resulting amplicon was ligated into pPD95-69.  For dre-1 cDNA 
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rescue constructs, the dre-1 cDNA was amplified from purified mixed stage C. 
elegans cDNA and ligated via TOPO cloning into the pCRII-TOPO vector 
(Invitrogen).  From this template, the dre-1 cDNA was amplified with primers 
including SpeI and SalI sites, and the resulting amplicon ligated into pBluescript.  
The dre-1 3'UTR was amplified by PCR from genomic DNA and ligated with SalI 
and ApaI sites downstream of the dre-1 cDNA in this plasmid.  Finally, various 
promoters were amplified from genomic DNA and ligated using NotI and SpeI 
sites: 4.4 kb of genomic DNA upstream of the aff-1 ATG was used for aff-
1p::DRE-1 plasmids; 730 bp of genomic DNA upstream of the dpy-30 ATG was 
used for dpy-30p::DRE-1 plasmids.  dre-1 mutations were introduced into the 
cDNA by PCR.  Briefly, two anti-parallel primers containing the desired mutation 
were used along with primers complementary to the beginning and end of the 
cDNA to produce two PCR products that included the desired mutation.  These 
products were then used as the template for a third PCR in which primers 
complementary to the beginning and end of the cDNA were used.  The resulting 
amplicon was ligated into the plasmid described above in place of the wild-type 
cDNA.  This strategy was used to create the aff-1p::DRE-1(2218) and aff-
1p::DRE-1(1960) mutant forms of the cDNA.  Drosophila S2 cell culture 
transfections were done with the relevant cDNA cloned into the pAC5.1 vector. 
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Transgenic strains 
All rescue experiments were performed using 5 ng/ul rescuing plasmid or fosmid 
+ 15 ng/ul coelomocyte::dsRed coinjection marker (a gift from Carl Procko) + 80 
ng/ul pBluescript.  Fluorescent reporters were injected at 25 ng/ul with pRF4 rol-6 
plasmid. 
 
Immunostaining with anti-CED-9 antibodies 
Immunostaining was attempted as described by Finney and Ruvkun (1990), as 
well as with the freeze-crack method of Janet Duerr.  Goat anti-CED-9 antibodies 
were used at 1:50-1:200 concentrations. 
 
Drosophila S2 cell culture 
S2 cells were grown in Shields and Sang M3 insect medium with 10% FBS and 
penn-strep at 50 units/ml at 25oC.  For transfections, 2 million cells in 2 ml culture 
medium were split into 6 well plates, and the following day cells were transfected 
with 1 ug plasmid DNA + 8 ul Fugene HD Transfection Reagent (Roche).  
Analysis was performed 3 days later. 
 
Immunoprecipitation 
2-10 ml transfected cells were pelleted by centrifugation and washed with 1 ml 
cold PBS.  Cells were lysed in 500 ul NP-40 lysis buffer with 250 mM NaCl for 1 
hour at 4oC.  myc::CED-9 was immunoprecipitated with rabbit polyclonal anti-myc 
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(AbCam) + Dynabeads (Invitrogen) for 30 min at 20oC.  The complexes were 
isolated and washed according to the manufacturer's directions and analyzed by 
SDS-PAGE. 
 
RNA interference 
HT1114 E. coli carrying the relevant RNAi plasmid were grown overnight at 37oC 
in LB+ampicillin.  Bacteria were plated on NGM+IPTG+carbenicillin plates and 
incubated at 37oC with the lids askew for 3 hours to dry, followed by upside-down 
overnight to grow.  The following day, rrf-3(pk1426);nsIs25 young adult 
hermaphrodites were placed on the lawn.  For the next two days, L1 progeny 
were scored for tail-spike cell survival under a compound fluorescence 
microscope. 
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